[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"endometrial-cancer\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:endometrial-cancer":32},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,259,0,25,[9,60,102,138,172,196,220,259,289,311,338,386,414,441,469,491,519,541,563,586,617,638,658,691,756],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":16,"eligibilityCriteria":17,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":20,"enrollmentInfo":21,"targetDuration":4,"studyType":24,"phases":25,"briefSummary":28,"conditions":29,"keywords":34,"overallStatus":47,"whyStopped":4,"lastUpdateSubmitDate":48,"lastUpdatePostDateStruct":49,"startDateStruct":52,"completionDateStruct":54,"leadSponsor":56,"locationsCount":59},"100500508","phase-1-phase-iiia-study-of-azd5335-as-monotherapy-and-combination-therapy-in-participants-with-solid-tumors-100500508",false,"NCT05797168","Phase I\u002FIIa Study of AZD5335 as Monotherapy and Combination Therapy in Participants With Solid Tumors","A Modular Phase I\u002FIIa, Open-label Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of Ascending Doses of AZD5335 Monotherapy and in Combination With Anti-cancer Agents in Participants With Solid Tumors","FONTANA","Core Inclusion Criteria:\n\n* Capable of giving signed informed consent, which includes compliance with the requirements and restrictions listed in the ICF and in this protocol.\n* Provision of signed and dated written Optional Genetic Research Information informed consent prior to collection of samples for optional genetic research that supports Genomic Initiative. Participants who do not provide informed consent for Optional Genetic Research may still be enrolled in the study.\n* Participant must be ≥ 18 years at the time of signing the informed consent.\n* Willing to provide adequate archival and\u002For baseline tumor sample as applicable per module-specific criteria.\n* For participants who have previously received targeted therapies such as ADCs, a fresh baseline biopsy will be required unless the most recent archival tissue sample was collected after receipt of such treatment.\n* Eastern Cooperative Oncology Group Performance Status of 0 or 1.\n* Participants with advanced solid tumors must have received prior adequate therapy in accordance with local practice for their tumor type and stage of disease, or, in the opinion of the Investigator, a clinical trial is the best option for the next treatment based on response and\u002For tolerability to prior therapy. Participants with contraindications or who refuse therapy in accordance with local practice may also be considered provided that it is documented that he\u002Fshe was informed about all therapeutic options.\n* Participants must have measurable disease per RECIST v1.1,\n\n  1. A previously irradiated lesion can be considered a target lesion if the lesion is progressing and well defined.\n  2. For participants who undergo biopsies at screening and\u002For on treatment, it is preferred though not required, that the biopsied lesion, be distinct from any target lesion used in the RECIST v1.1 evaluation.\n* Life expectancy ≥ 12 weeks.\n* Adequate organ and marrow function.\n* Contraceptive use by men or women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.\n\n  (a) Male participants: (i) Male participants who are sexually active with a female partner of childbearing potential must use a male condom (plus an additional contraceptive method) post-screening for at least 8 months following the last dose of study intervention. It is strongly recommended for the female partner of a male participant to also use a highly effective method of contraception throughout this period. In addition, male participants must refrain from freezing or donating sperm while on study and for 8 months following the last dose of study intervention.\n\n  (b) Female participants : (i) Females of childbearing potential must have a negative serum pregnancy test result within 72 hours prior to receiving the first dose of study intervention and a negative urine or serum pregnancy test prior to starting their next cycle of treatment. If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required.\n\n(ii) (ii) Sex and Contraceptive\u002FBarrier Requirements: Highly effective birth control methods include: Total sexual abstinence is an acceptable method provided it is the usual lifestyle of the participant (defined as refraining from heterosexual intercourse during the entire period of risk associated with the study treatments) \\[(periodic abstinence e.g., calendar, ovulation, symptothermal, post-ovulation methods), declaration of abstinence for the duration of exposure to study intervention, and withdrawal are not acceptable methods of contraception\\], a vasectomized partner, Implanon®, bilateral tubal occlusion, intrauterine device\u002Flevonorgestrel intrauterine system, Depo Provera™ injections, oral contraceptive associated with inhibition of ovulation, and Evra Patch™, Xulane™, or NuvaRing®.\n\nFemale participants of childbearing potential who are sexually active with a non-sterilized male partner must agree to use one highly effective method of birth control (defined as one that can achieve a failure rate of less than 1% per year when used consistently and correctly), from enrolment throughout the study and for 8 months following the last dose of study intervention. The male partner of a female participant of childbearing potential must also use a male condom (plus spermicide, if available) throughout this period. Cessation of contraception after this point should be discussed with a responsible physician. In addition, female participants must not donate or retrieve for their own use, ova while on study and for 8 months following the last dose of study intervention.\n\nCore Exclusion Criteria:\n\n* Patients with spinal cord compression or a history of leptomeningeal carcinomatosis.\n* Patients with brain metastases unless, asymptomatic, stable, and not requiring continuous corticosteroids at a dose of \\> 10 mg prednisone\u002Fday or equivalent for at least 4 weeks prior to first dose of study intervention.\n* Treatment with any of the protocol defined medications, without adequate washout periods or time before the first dose of study intervention.\n* Unresolved toxicities of Grade ≥ 2 (National Cancer Institute \\[NCI\\] CTCAE v5.0) from prior therapy (excluding vitiligo, alopecia, and endocrine disorders that are controlled with replacement hormone therapy). Participants with stable ≤ Grade 2 neuropathy are eligible.\n* Active infection, including tuberculosis and infections with hepatitis B virus (HBV; verified by known positive hepatitis B surface antigen \\[HBsAg\\] result), hepatitis C virus (HCV) or known HIV infection that is not well controlled. All of the following criteria are required to define an HIV infection that is well controlled: undetectable viral RNA, CD4+ count ≥ 350\u002Fmm3, no history of acquired immune deficiency syndrome-defining opportunistic infection within the past 12 months, and stable for at least 4 weeks on the same anti-HIV medications (meaning there are no expected further changes in that time to the number or type of antiretroviral drugs in the regimen).\n\nPatients with a past or resolved HBV\u002FHCV infection are eligible if:\n\n1. Negative for HBsAg and positive for anti-hepatitis B virus core protein (HBc) or\n2. Are HBsAg + with chronic HBV infection (lasting 6 months or longer) and meet conditions i-iii below:\n\n(i) HBV DNA viral load \\\u003C100 IU\u002FmL. (ii) Have normal transaminase values, or, if liver metastases are present, abnormal transaminases, with a result of aspartate aminotransferase (AST)\u002Falanine aminotransferase (ALT) \\\u003C3 x upper limit of normal (ULN), which are not attributable to HBV infection.\n\n(iii) Start or maintain antiviral treatment if clinically indicated as per the Investigator or as per local guideline.\n\nNote for Japan: Japanese patients with positive anti-HBs\u002Fanti-HBc and negative HBsAg will be assessed following local guidelines.\n\n(c) Participants testing positive for HCV antibody are eligible only if the polymerase chain reaction test result is negative for HCV RNA.\n\n* Patient has active ILD\u002Fpneumonitis or has a history of (non-infectious) ILD\u002Fpneumonitis that required oral or IV steroids or supplemental oxygen, or where suspected ILD\u002Fpneumonitis cannot be ruled out by imaging at screening.\n\n  * Patients with a history of radiation pneumonitis which has clinically and radiologically resolved and not requiring treatment with steroids may be eligible.\n* History of another malignancy except for:\n\n  * Malignancy treated with curative intent and with no known active disease for at least 2 years prior to screening of study intervention and with low potential risk for recurrence.\n  * Adequately treated non-melanoma skin cancer or lentigo maligna without evidence of disease.\n  * Adequately treated carcinoma in situ without evidence of disease.\n  * Localized non-invasive solid organ primary disease under surveillance.\n* Patients with any of the following cardiac criteria:\n\n  * History of arrhythmia (such as multifocal premature ventricular contractions, bigeminy, trigeminy, and ventricular tachycardia), which is symptomatic or requires treatment NCI CTCAE v5.0 Grade 3 except for:\n\n    (i) Rate controlled asymptomatic atrial fibrillation.\n    * NOTE: significant abnormalities in serum electrolytes that can increase the risk of arrhythmic events (ie, sodium, potassium, calcium, and magnesium) should be corrected before starting the study intervention.\n  * Uncontrolled hypertension.\n  * Acute coronary syndrome\u002Facute myocardial infarction, unstable angina pectoris, coronary intervention procedure with percutaneous coronary intervention, or coronary artery bypass grafting within 6 months of screening.\n  * History of brain perfusion problems (eg, carotid stenosis) or stroke, or transient ischemic attack in the last 6 months prior to screening.\n  * Symptomatic heart failure (as defined by New York Heart Association class ≥ 2).\n  * Prior or current diagnosis of cardiomyopathy considered clinically relevant per investigator's judgement.\n  * Severe uncorrected valvular heart disease.\n  * Mean resting QTcF \\> 470 msec obtained from triplicate electrocardiograms (ECGs) and averaged, recorded within 5 minutes.\n  * Any factor that, in the opinion of the investigator, increases the proarrhythmic risk of QT prolongation, such as congenital long QT syndrome, family history of long QT syndrome, hypertrophic cardiomyopathy, or unexplained sudden cardiac death under 40 years of age.\n* Uncontrolled and\u002For unresolved intercurrent illness within 12 months prior to screening, including but not limited to serious chronic gastrointestinal conditions associated with diarrhea, or illness (including psychiatric illness) and\u002For social situations, in the opinion of the investigator, that would limit compliance with study requirements and activities, substantially increase risk of incurring AEs or compromise the ability of the participant to give written informed consent.\n* Substance abuse or any other medical conditions that would increase the safety risk to the participant or interfere with participation of the participant or evaluation of the clinical study in the opinion of the Investigator.\n* Receipt of live attenuated vaccine within 30 days prior to the first dose of study intervention. Note: Participants, if enrolled, should not receive live vaccine whilst receiving study intervention and up to 3 months after the last dose of study intervention. Participants can receive Coronavirus (COVID)-19 vaccines, at the discretion of the Investigator, following a benefit\u002Frisk evaluation for the individual participant and in accordance with local rules and regulations and vaccination guidelines. Note: If a COVID-19 vaccine is administered it should be done \\> 72 hours prior to study intervention initiation or after completion of the DLT period.\n* For women only - currently pregnant (confirmed with positive pregnancy test or suspected), lactating, breastfeeding, or intention to become pregnant during the study period.\n* Concurrent enrolment in another clinical study, unless it is an observational (non interventional) clinical study or during the follow-up period of an interventional study. Exception: Diagnostic imaging evaluation studies (e.g. PET) may be allowed subject to case-by-case discussion with the Sponsor.\n* Patients with a known hypersensitivity to study intervention or any of the excipients of the product.\n* Involvement in the planning and\u002For conduct of the study (applies to both AstraZeneca staff and\u002For staff at the study site).\n* Judgment by the Investigator that the patient should not participate in the study if the patient is unlikely to comply with study procedures, restrictions and requirements.\n* Previous enrolment in the present study. \\*\\*Other module specific criteria may apply","ALL","18 Years","130 Years",{"count":22,"type":23},602,"ESTIMATED","INTERVENTIONAL",[26,27],"PHASE1","PHASE2","This research is designed to determine if experimental treatment with Antibody-drug conjugate, AZD5335, alone, or in combination with anti-cancer agents is safe, tolerable, and has anti-cancer activity in patients with advanced tumors",[30,31,32,33],"Ovarian Cancer","Lung Adenocarcinoma","Endometrial Cancer","Lung Squamous Cell Carcinoma",[35,36,37,38,39,40,41,42,43,44,45,46,30,31,32,33],"ADC","PARP inhibitor","AZD5335","Torvutatug Samrotecan","Torvu-sam","AZD5305","Saruparib","Bevacizumab","Carboplatin","AZD9574","Palacaparib","Pembrolizumab","RECRUITING","2026-08-20",{"date":50,"type":51},"2026-08-21","ACTUAL",{"date":53,"type":51},"2023-06-05",{"date":55,"type":23},"2028-08-04",{"name":57,"class":58},"AstraZeneca","INDUSTRY",60,{"id":61,"slug":62,"hasResults":12,"nctId":63,"briefTitle":64,"officialTitle":65,"acronym":4,"eligibilityCriteria":66,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":67,"enrollmentInfo":68,"targetDuration":4,"studyType":24,"phases":70,"briefSummary":71,"conditions":72,"keywords":84,"overallStatus":47,"whyStopped":4,"lastUpdateSubmitDate":93,"lastUpdatePostDateStruct":94,"startDateStruct":95,"completionDateStruct":97,"leadSponsor":99,"locationsCount":101},"100639777","phase-1-a-first-in-human-study-of-hh160-in-patients-with-advanced-solid-tumors-100639777","NCT07623369","A First-in-Human Study of HH160 in Participants With Advanced or Metastatic Solid Tumors","An Open-Label, Multicenter, Phase 1 Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, Immunogenicity and Preliminary Antitumor Activity of HH160 Alone or in Combination With Other Antitumor Agents in Patients With Advanced or Metastatic Solid Tumors","Key Inclusion Criteria\n\n1. Adults aged 18 to 75 years with signed informed consent.\n2. Histologically or cytologically confirmed advanced solid tumors meeting phase-specific disease requirements.\n3. At least 1 measurable lesion per RECIST v1.1.\n4. Eastern Cooperative Oncology Group Performance Status (ECOG) Performance Status of 0 or 1 with life expectancy ≥ 12 weeks.\n5. Adequate organ function based on protocol-specified laboratory criteria.\n\nKey Exclusion Criteria\n\n1. Active leptomeningeal disease or uncontrolled\u002Funtreated brain metastases.\n2. History of severe hypersensitivity reactions to monoclonal antibodies, bispecific antibodies, trispecific antibodies, or study drug components.\n3. Other malignancy within 3 years prior to first dose, except specified curatively treated cancers.\n4. Uncontrolled pleural effusion, pericardial effusion, or ascites requiring frequent drainage.\n5. Significant bleeding risk, severe coagulopathy, gastrointestinal hemorrhage, or recent pulmonary hemorrhage\u002Fhemoptysis.\n\nNOTE: Other eligibility criteria may apply.","75 Years",{"count":69,"type":23},299,[26],"This study is evaluating the safety, side effects, how the body processes HH160, and its early anticancer activity when given alone or with other cancer treatments in participants with advanced solid tumors. The study will also identify the recommended dose for future studies. The trial includes two phases and is expected to last about 4 years, with treatment and follow-up lasting approximately 6-12 months each.",[73,74,75,76,77,78,32,79,80,81,82,83],"Solid Tumor","Non-small Cell Lung Cancer","Hepatocellular Carcinoma","Colorectal Cancer","Head and Neck Squamous Cell Carcinoma","Renal Cell Carcinoma","Cervical Cancer","Small-cell Lung Cancer","Triple Negative Breast Cancer","Urothelial Carcinoma","Gastroesophageal Adenocarcinoma",[85,86,74,87,75,88,76,89,90,77,78,91,32,79,80,81,92,82,83,30],"HH160","PD-1×CTLA-4×VEGF-A Antibody","NSCLC","HCC","CRC","GEA","RCC","TNBC","2026-08-19",{"date":50,"type":51},{"date":96,"type":51},"2026-06-11",{"date":98,"type":23},"2028-08",{"name":100,"class":58},"Huahui Health",3,{"id":103,"slug":104,"hasResults":12,"nctId":105,"briefTitle":106,"officialTitle":107,"acronym":108,"eligibilityCriteria":109,"healthyVolunteers":12,"sex":110,"minAge":19,"maxAge":4,"enrollmentInfo":111,"targetDuration":4,"studyType":113,"phases":4,"briefSummary":114,"conditions":115,"keywords":120,"overallStatus":47,"whyStopped":4,"lastUpdateSubmitDate":93,"lastUpdatePostDateStruct":130,"startDateStruct":131,"completionDateStruct":133,"leadSponsor":135,"locationsCount":137},"100634822","endometrial-cancer-vaginal-fluid-specimen-collection-study-100634822","NCT07544680","Endometrial Cancer Vaginal Fluid Specimen Collection Study","Endometrial Cancer Vaginal Fluid Specimen Collection Study: \"ENVISION\"","ENVISION","Inclusion Criteria\n\nCohort 1 Participants:\n\n* Age ≥ 45 years, OR age ≥ 18 years with at least one risk factor\n* Diagnosed with abnormal uterine bleeding (AUB)\n* Planning standard-of-care endometrial tissue sampling to assess for endometrial cancer (EC) or atypical endometrial hyperplasia\u002Fendometrial intraepithelial neoplasia (AEH\u002FEIN)\n\nCohort 2 Participants:\n\n* Age ≥ 18 years\n* Newly diagnosed, biopsy-confirmed EC or AEH\u002FEIN\n* Planning initial management for their endometrial pathology\n\nExclusion Criteria\n\n* Prior partial or complete hysterectomy\n* Current pregnancy\n* Prior pelvic or vaginal radiotherapy\n* Chemotherapy within past 5 years (except tamoxifen)\n* Any condition judged by the Investigator to preclude participation\n\nAdditional for Cohort 1:\n\n* Cancer diagnosis within past 5 years (except non-gynecologic skin cancer)\n* Current biopsy-proven cervical, vaginal, or vulvar cancer, or lower genital tract dysplasia\n* Current biopsy-proven endometrial cancer, hyperplasia, or benign polyp\n* Benign endometrial biopsy within last month\n\nAdditional for Cohort 2:\n\n* Cancer diagnosis other than EC within past 5 years (except non-gynecologic skin cancer)\n* Prior cervical cancer or biopsy-proven cervical dysplasia\n* Surgery for recurrent EC\n* Preoperative neoadjuvant chemotherapy or radiotherapy for current EC\n* Prior treatment or surgery to remove target pathology during current episode","FEMALE",{"count":112,"type":23},4200,"OBSERVATIONAL","This is a multicenter, prospective, specimen collection study for development and evaluation of tests used to detect endometrial cancer, other cancers, or their causes.",[116,32,117,118,119],"Abnormal Uterine Bleeding (AUB)","Atypical Endometrial Hyperplasia","Endometrial Hyperplasia With Atypia","Endometrial Intraepithelial Neoplasia",[116,121,122,123,124,125,126,127,128,129],"Endometrial Cancer (EC)","Atypical Endometrial Hyperplasia (AEH)","Endometrial Hyperplasia with Atypia","Endometrial Intraepithelial Neoplasia (EIN)","Precancerous Conditions","Post-Menopausal Bleeding","Specimen Collection","Sample Collection","in vitro diagnostic (IVD) devices",{"date":48,"type":51},{"date":132,"type":51},"2026-03-10",{"date":134,"type":23},"2028-04-24",{"name":136,"class":58},"Exact Sciences Corporation",5,{"id":139,"slug":140,"hasResults":12,"nctId":141,"briefTitle":142,"officialTitle":143,"acronym":4,"eligibilityCriteria":144,"healthyVolunteers":12,"sex":18,"minAge":145,"maxAge":4,"enrollmentInfo":146,"targetDuration":4,"studyType":24,"phases":148,"briefSummary":150,"conditions":151,"keywords":156,"overallStatus":47,"whyStopped":4,"lastUpdateSubmitDate":93,"lastUpdatePostDateStruct":163,"startDateStruct":164,"completionDateStruct":166,"leadSponsor":168,"locationsCount":171},"100610399","dosing-physical-activity-among-older-cancer-survivors-who-experience-chronic-pain-a-micro-randomized-trial-100610399","NCT07227077","Dosing Physical Activity Among Older Cancer Survivors Who Experience Chronic Pain: a Micro-randomized Trial","An Adaptive Design for Dosing Physical Activity Among Older Cancer Survivors Who Experience Chronic Pain: a Micro-randomized Trial","Inclusion Criteria:\n\n1. Age greater than or equal to 65 years.\n2. Patients with a history of bladder, breast, cervical, colorectal, endometrial, lung, and prostate cancer diagnosis and treatment.\n3. Fluent in spoken and written English.\n4. Patient has access to smartphone\n5. Ability to understand a written informed consent document, and the willingness to sign it.\n\nExclusion Criteria:\n\n1. Patient has metastatic disease.\n2. Patient has cancer recurrence.","65 Years",{"count":147,"type":23},50,[149],"NA","The purpose of this study is to assess the best time to deliver a message to increase physical activity and how often participants will experience a pain episode in the 24 hours following their receipt of a message to increase physical activity.",[152,79,153,76,32,154,155],"Breast Cancer","Bladder Cancer","Lung Cancer","Prostate Cancer",[157,158,159,160,161,162],"Physical Activity","Exercise","Survivorship","Supportive Care","Pain","Symptom Management",{"date":48,"type":51},{"date":165,"type":51},"2026-02-07",{"date":167,"type":23},"2027-05-01",{"name":169,"class":170},"Medical College of Wisconsin","OTHER",1,{"id":173,"slug":174,"hasResults":12,"nctId":175,"briefTitle":176,"officialTitle":176,"acronym":4,"eligibilityCriteria":177,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":178,"targetDuration":4,"studyType":24,"phases":180,"briefSummary":181,"conditions":182,"keywords":184,"overallStatus":47,"whyStopped":4,"lastUpdateSubmitDate":93,"lastUpdatePostDateStruct":188,"startDateStruct":189,"completionDateStruct":191,"leadSponsor":193,"locationsCount":195},"100601379","phase-1-a-phase-12-trial-of-ter-2013-in-patients-with-solid-tumors-harboring-aktpi3kpten-pathway-alterations-100601379","NCT07109726","A Phase 1\u002F2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT\u002FPI3K\u002FPTEN Pathway Alterations","Key Inclusion Criteria\n\n* Metastatic or locally advanced, unresectable disease\n* No available treatment with curative intent\n* Presence of lesions to be evaluated per RECIST v1.1:\n\n  a. Dose Escalation: measurable or evaluable disease b. Cohort Expansion: measurable disease\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1\n* Adequate organ function\n* Advanced solid tumor malignancy harboring an eligible AKT\u002FPI3K\u002FPTEN pathway alteration detected by a sponsor approved test\n\nKey Inclusion Criteria for TER-2013 monotherapy arms:\n\n* Histologically confirmed diagnosis of:\n\n  a. \\[For TER-2013 dose escalation\\]: solid tumor malignancy b. \\[For TER-2013 cohort expansion\\]: i. Cohort 1: ovarian cancer, cervical cancer, or squamous cell carcinoma of the head and neck, lung, or esophagus ii. Cohort 2: endometrial adenocarcinoma\n* Prior therapy:\n\n  1. \\[For TER-2013 dose escalation\\]: Received standard therapies appropriate for their tumor type and stage, unless contraindicated, intolerable, or patient refused\n  2. \\[For TER-2013 cohort expansion\\]: No more than 3 prior lines of treatment in the advanced setting\n\n     Key Inclusion Criteria for TER-2013 and fulvestrant combination arms\n* Histologically confirmed diagnosis of:\n\n  a. \\[For TER-2013 + fulvestrant dose escalation\\]: HR+\u002FHER2- advanced unresectable or metastatic breast cancer b. \\[For TER-2013 + fulvestrant cohort expansion\\]: i. Received treatment with an AI containing regimen (single agent or in combination) ii. No more than 3 prior lines of treatment in the advanced unresectable or metastatic setting\n* Prior Therapy:\n\n  a. \\[For TER-2013 + fulvestrant dose escalation\\]: Received treatment with an AI containing regimen (single agent or in combination) b. \\[For TER-2013 + fulvestrant cohort expansion\\]: i. Received treatment with an AI containing regimen (single agent or in combination) ii. No more than 3 prior lines of treatment in the advanced unresectable or metastatic setting\n\nKey Exclusion Criteria:\n\n* Known EGFR, KRAS, NRAS, HRAS, or BRAF oncogenic-driver co-mutation with PI3K\u002FAKT\u002FPTEN alteration\n* Clinically significant abnormalities of glucose metabolism\n* Active brain metastases or carcinomatous meningitis.\n* History of significant hemoptysis or hemorrhage within 4 weeks prior to first dose of study drug\n* Malabsorption syndrome, nausea and vomiting uncontrolled by medication, or disease significantly affecting gastrointestinal function likely to interfere with the delivery, absorption, or metabolism of TER-2013\n* Prior therapy:\n\n  1. \\[For TER-2013 monotherapy escalation\\]: AKT inhibitor\n  2. \\[For TER-2013 monotherapy expansion\\]: AKT\u002FPI3K\u002FPTEN pathway inhibitor\n  3. \\[For TER-2013 + fulvestrant combination expansion\\]: AKT\u002FPI3K\u002FPTEN pathway inhibitor, fulvestrant and other SERDs, mTOR inhibitor; some PIK3CA-altered cohorts allow prior PI3K inhibitor.\n\nOther protocol-defined Inclusion\u002FExclusion Criteria apply",{"count":179,"type":23},205,[26,27],"This is a Phase 1\u002F2, open-label, multicenter study evaluating the safety, tolerability, pharmacokinetics, pharmacodynamics and anti-tumor activity of TER-2013 in patients with advanced solid tumors harboring AKT\u002FPI3K\u002FPTEN pathway alterations.",[152,32,30,33,77,183,73,79],"Esophageal Squamous Cell Carcinoma",[185,152,186,187],"AKT\u002FPI3K\u002FPTEN Alterations","Advanced Solid Tumors","HR+\u002FHER2-",{"date":50,"type":51},{"date":190,"type":51},"2025-09-23",{"date":192,"type":23},"2029-02-28",{"name":194,"class":58},"Terremoto Biosciences Inc.",18,{"id":197,"slug":198,"hasResults":12,"nctId":199,"briefTitle":200,"officialTitle":201,"acronym":202,"eligibilityCriteria":203,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":204,"targetDuration":4,"studyType":24,"phases":206,"briefSummary":207,"conditions":208,"keywords":4,"overallStatus":47,"whyStopped":4,"lastUpdateSubmitDate":93,"lastUpdatePostDateStruct":212,"startDateStruct":213,"completionDateStruct":215,"leadSponsor":217,"locationsCount":219},"100575644","phase-1-a-phase-1-study-of-lncb74-in-advanced-solid-tumors-100575644","NCT06774963","A Phase 1 Study of LNCB74 in Advanced Solid Tumors","A Phase 1, Open-label, Dose Escalation and Dose Expansion Study for LNCB74, a B7-H4 Targeted Antibody Drug Conjugate, as Monotherapy in Participants With Advanced Solid Tumors","LNCB74-01","Inclusion Criteria:\n\n1. The participant provides written informed consent\n2. ≥ 18 years of age on day of signing informed consent.\n3. Participant with histologically or cytologically confirmed diagnosis of advanced unresectable and\u002For metastatic solid tumors\n4. A male participant must agree to use contraception and refrain from sperm donation or expecting to father a child\n5. A female participant is eligible to participate if she is not pregnant, not breastfeeding, not a woman of childbearing potential\n6. Have measurable disease per RECIST 1.1 as assessed by the local site investigator\u002Fradiology\n7. Able to provide tumor tissue sample.\n8. Willing to undergo fresh tumor biopsy at Screening and On-treatment if archival tissue not available\n9. Have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1\n10. Life expectancy greater than or equal to 12 weeks as judged by the Investigator.\n11. Have adequate organ function\n\nExclusion Criteria:\n\n1. A WOCBP who has a positive serum pregnancy test (within 72 hours) prior to treatment.\n2. Has received prior investigational agents within 4 weeks prior to treatment.\n3. Has received anti-cancer chemotherapy (Immunotherapy (non-antibody-based therapy), retinoid therapy, hormonal therapy within 2 weeks prior to treatment.\n4. Has received antibody-based anti-cancer therapy within 4 weeks prior to treatment.\n5. Has received targeted agents and small molecules within 2 weeks or 5 half-lives, whichever is longer.\n6. Has received prior platinum-based chemotherapy and progressed within 4 weeks of initiating therapy (platinum-refractory disease)\n7. Has received an ADC with MMAE payload.\n8. Has received prior radiotherapy within 2 weeks of start of study treatment for focal radiation or within 4 weeks for wide-field radiotherapy\n9. Has received G-CSF or GM-CSF within 7 days prior to start of study treatment.\n10. Has received a live or live-attenuated vaccine within 30 days prior to the first dose of study intervention.\n11. Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy (in dosing exceeding 10 mg daily of prednisone equivalent) or any other form of immunosuppressive therapy within 7 days prior to the first dose of study drug\n12. Has a known additional malignancy that is progressing or has required active treatment within the past 3 years\n13. Has known active CNS metastases and\u002For carcinomatous meningitis\n14. Has severe hypersensitivity (≥ Grade 3), known allergy or reaction LNCB74 or any of its excipients.\n15. Has a history of (non-infectious) pneumonitis \u002F interstitial lung disease that required steroids or has current pneumonitis \u002F interstitial lung disease.\n16. Has active ≥Grade 2 sensory or motor neuropathy.\n17. Has active or chronic corneal disorders, other active ocular conditions requiring ongoing therapy or any clinically significant corneal disease.\n18. Has an active infection requiring systemic therapy.\n19. Any major surgery within 4 weeks of study drug administration.\n20. Toxicity (except for alopecia) related to prior anti-cancer therapy and\u002For surgery, unless the toxicity is either resolved, returned to baseline or Grade 1, or deemed irreversible.\n21. Prior organ or tissue allograft.\n22. Uncontrolled or significant cardiovascular disease\n23. Participants with serious or uncontrolled medical disorders.\n24. Participants who are on total parenteral nutrition (TPN)\n25. Participants with history of bowel obstruction within one month of screening\n26. Participants with history of significant ascites requiring paracentesis within 2 weeks of screening\n27. Has a known history of human immunodeficiency virus (HIV) infection with an acquired immune deficiency syndrome (AIDS)-defining opportunistic infection within the last year, or a current CD4 count \\\u003C350 cells\u002Fµl\n28. Has known active Hepatitis B (defined as HBsAg reactive) or known active Hepatitis C virus (defined as HCV RNA \\[qualitative\\] is detected) infection\n29. Has a history or current evidence of any condition, therapy, or laboratory abnormality, or other circumstance that might confound the results of the study or interfere with the participant's participation for the full duration of the study\n30. Has a known psychiatric or substance abuse disorder that would interfere with the participant's ability to cooperate with the requirements of the study",{"count":205,"type":23},145,[26],"This is an open-label, phase 1, dose escalation and dose expansion study to determine safety and tolerability, and to determine the maximum tolerated dose and \u002F or recommended phase 2 dose of LNCB74 in participants with advanced solid tumors.",[30,152,32,209,210,211],"Biliary Tract Cancer","Non-Small Cell Lung Cancer","Advanced or Metastatic Solid Tumors",{"date":50,"type":51},{"date":214,"type":51},"2025-01-07",{"date":216,"type":23},"2026-12",{"name":218,"class":58},"NextCure, Inc.",14,{"id":221,"slug":222,"hasResults":12,"nctId":223,"briefTitle":224,"officialTitle":225,"acronym":4,"eligibilityCriteria":226,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":227,"targetDuration":4,"studyType":24,"phases":229,"briefSummary":230,"conditions":231,"keywords":240,"overallStatus":47,"whyStopped":4,"lastUpdateSubmitDate":93,"lastUpdatePostDateStruct":251,"startDateStruct":252,"completionDateStruct":254,"leadSponsor":256,"locationsCount":258},"100529338","a-study-of-her3-dxd-in-subjects-with-locally-advanced-or-metastatic-solid-tumors-100529338","NCT06172478","A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors","HERTHENA-PanTumor01 (U31402-277): A Phase 2, Multicenter, Multicohort, Open-Label, Proof of Concept Study of Patritumab Deruxtecan (HER3-DXd; U3-1402) in Subjects With Locally Advanced or Metastatic Solid Tumors","Inclusion Criteria\n\nParticipants must meet all of the following criteria to be eligible for enrollment into the study:\n\n1. Sign and date the informed consent form prior to the start of any study-specific qualification procedures. A separate tissue screening consent will be obtained from all subjects to meet the baseline tumor tissue requirement.\n2. Participants aged ≥18 years (follow local regulatory requirements if the legal age of consent for study participation is \\>18 years old).\n3. Has locally advanced unresectable or metastatic disease (not curable by surgery or radiation) as follows:\n\n   Cutaneous (acral and non-acral) melanoma\n   1. Histologically or cytologically confirmed cutaneous (acral or non-acral) melanoma\n   2. Disease progression while on or after having received treatment with ≥1 prior line of anti-programmed cell death protein (PD-1) or anti-programmed death-ligand 1 (PD-L1) based therapy (previous use of other immune checkpoint inhibitors \\[ICIs\\] \\[ie, anti-CTLA4, anti- LAG-3\\] is acceptable). Prior anti-PD-(L)1 therapy in the adjuvant setting is allowed if there is recurrence within 12 weeks of the last dose. If the participant had BRAFm melanoma, they must have had disease progression on BRAF\u002FMEK inhibitor therapy as well.\n\n      Squamous cell carcinomas of the head and neck\n   3. Squamous cell carcinoma of the head and neck (with a primary location of oral cavity,oropharynx, larynx, hypopharynx) that is human papillomavirus (HPV) positive or negative (as determined by local standard). Excludes tumor location in the nasopharynx, nasal cavity, paranasal sinuses, and unknown primary locations.\n   4. Disease progression after having received treatment with ≥1 and \\\u003C3 prior lines of systemic therapy in the unresectable recurrent or metastatic setting.\n\n      Must have had disease progression on anti-PD-(L)1 (either as monotherapy or in combination with chemotherapy or other therapies). Must also have had disease progression on a platinum-based chemotherapy (PBC) regimen either in the recurrent or metastatic setting or in the locally advanced setting with curative intent.\n\n      Gastric or GEJ adenocarcinoma\n   5. Tumor tissue must be confirmed as negative for HER2 expression (immunohistochemistry \\[IHC\\] 0\u002F1+ or IHC 2+\u002Fin situ hybridization negative) as classified by American Society of Clinical Oncology\u002FCollege of American Pathologists (ASCO-CAP) guidelines and determined prior to enrollment by assessment in a local laboratory that is Clinical Laboratory Improvement Amendments certified (US sites) or accredited based on specific country regulations.\n   6. Disease progression after having received treatment with ≥2 prior lines of therapy that include PBC with or without anti-PD-1 therapy.\n\n      Ovarian Carcinoma\n   7. Pathologically documented high-grade serous epithelial ovarian cancer, primary peritoneal cancer, or fallopian tube cancer.\n   8. Documented disease progression ≥4 weeks after the last dose of PBC and \\\u003C6 months of last dose of PBC in the advanced or metastatic setting. Prior use of folate reductase alpha targeting antibody-drug conjugate (ADC) (ie, mirvetuximab soravtansine) is allowed.\n\n      Cervical Cancer\n   9. Pathologically or cytologically documented recurrent or persistent squamous, adenosquamous, or adenocarcinoma of the uterine cervix.\n   10. Disease progression after having received ≥1 line of systemic therapy in the recurrent or metastatic setting. This may include prior anti-PD-(L)1 treatment and\u002For tissue factor directed ADC (tisotumab vedotin \\[TV\\]) per regional standard of care.\n\n       Endometrial Cancer\n   11. Pathologically or cytologically documented endometrial cancer (carcinoma of any histological sub-type or endometrial carcinosarcoma), irrespective of microsatellite instability (MSI) or mismatch repair (MMR) status.\n   12. Documented disease progression after having received ≥1 prior line of therapy (maximum of 3) PBC containing systemic treatment and an anti-PD(L)-1 therapy-containing regimen (combined or sequential) in the advanced\u002Fmetastatic setting.\n\n       Bladder Cancer\n   13. Pathologically or cytologically documented locally advanced\u002Funresectable or metastatic urothelial carcinoma of the bladder, renal pelvis, ureter, or urethra. Histological variants are allowed if urothelial histology is predominant. Small cell\u002Fneuroendocrine tumors are not allowed even if mixed histology.\n   14. Relapsed or progressed after treatment with ≥1 prior line of therapy (maximum of 3) that contains anti-PD-(L)1 therapy in the perioperative or metastatic setting. At least 1 line of therapy must also contain one of the following treatment modalities: chemotherapy or enfortumab vedotin. Prior fibroblast growth factor receptor (FGFR)-inhibitor treatment for those who are eligible are allowed.\n\n       * Required treatments can be given in combination or sequentially\n       * Prior cisplatin-based therapy or PD-(L)1 inhibitor therapy given for the treatment of muscle invasive urothelial carcinoma is counted as 1 line of therapy\n       * The same regimen administered twice in different disease settings will be counted as 1 line of prior therapy\n       * Participants in the second-line setting who have previously received enfortumab vedotin and pembrolizumab in combination can be enrolled.\n\n       Esophageal Carcinoma\n   15. Pathologically or cytologically documented esophageal squamous cell carcinoma.\n   16. Must have documented disease progression after having received 2 prior lines of therapy including previous PBC with or without an anti-PD-1 therapy-containing regimen (combined or sequential) in the advanced\u002Fmetastatic setting.\n\n       Pancreatic Carcinoma\n   17. Pathologically or cytologically documented unresectable or metastatic pancreatic adenocarcinoma.\n   18. Relapsed or disease progression after having received 1 prior line of systemic therapy in the locally advanced\u002Fmetastatic setting.\n\n       Prostate Cancer\n   19. Pathologically or cytologically documented unresectable locally advanced or metastatic castration-resistant prostate cancer (CRPC).\n   20. Adenocarcinoma of the prostate without neuroendocrine differentiation or small cell histology.\n   21. Surgically or medically castrated, with testosterone levels of \\\u003C50 ng\u002FdL.\n   22. Documented objective progression as determined by radiographic progression for subjects with measurable disease after androgen deprivation.\n   23. Relapsed or disease progression after having received treatment with ≥1 of the following novel hormonal agents: abiraterone, enzalutamide, apalutamide, or darolutamide.\n   24. Relapsed or disease progression after having received ≥1 cytotoxic chemotherapy regimen that included a taxane.\n\n       Gastric Cancer 2L\n   25. Must have had gastric or GEJ adenocarcinoma confirmed as negative for HER2 expression (IHC 0\u002F1+ or IHC 2+\u002Fin situ hybridization negative) as classified by American Society of Clinical Oncology\u002FCollege of American Pathologists (ASCO-CAP) guidelines and determined prior to enrollment by assessment in a local laboratory that is Clinical Laboratory Improvement Amendments certified (US sites) or accredited based on specific country regulations.\n   26. Disease progression after having received treatment with only 1 prior line of systemic anti-cancer therapy that includes 5-FU-based chemotherapy with or without an anti-PD-1 therapy. For subjects whose tumors are claudin (CLDN) 18.2 positive, treatment with 5-FU based chemotherapy with CLDN18.2 directed therapy in the first-line setting is allowed.\n\n   Non-small Cell Lung Cancer aa. Histologically or cytologically documented metastatic or locally advanced nonsquamous NSCLC not amenable to curative surgery or radiation bb. Documentation of absence of actionable driver mutation (ie, ALK rearrangement, BRAF V600E mutation, EGFR-activating mutations \\[exon 19 deletion or L858R mutation\\], EGFR exon 20 insertion mutation, HER2 mutation, KRAS G12C mutation, MET exon 14 skipping mutation, NTRK 1\u002F2\u002F3 gene fusion, RET rearrangement, or ROS1 rearrangement). New testing for these genomic alterations is not required for Screening.\n\n   cc. Relapsed or disease progression after receiving only anti-PD-(L)1 and PBC (ie, platinum doublet) administered in combination or sequentially for metastatic disease.\n\n   Breast Cancer dd. Pathologically documented breast cancer that is assessed as HER2 negative (IHC2+\u002FISH-, IHC1+, or IHC0 per ASCO\u002FCAP guidelines), and HR positive (either ER and\u002For PgR positive \\[ER or PgR ≥1%\\] per ASCO\u002FCAP guidelines). The HER2 and HR results must be from a tumor sample obtained in the metastatic setting.\n\n   ee. Participant must have received one line of chemotherapy for mBC, but not more than one line and must have a clinically or radiologically documented evidence of tumor progression on or after CDK 4\u002F6 inhibitor combined with endocrine therapy; previous treatments with phosphoinositide 3-kinase (PI3K) inhibitors, mammalian target of rapamycin (mTOR) inhibitors, protein kinase B (PKB) inhibitors also known as AKT-inhibitors and poly ADP ribose polymerase (PARP)-inhibitors are allowed.\n4. Has ≥1 measurable lesion on CT or MRI as per RECIST v1.1 by investigator assessment. Prostate cancer participants with bone only disease may be eligible.\n5. Provides a pretreatment tumor tissue sample that meets 1 of the following collection requirements:\n\n   1. Tumor biopsy from ≥1 lesion not previously irradiated and performed since progression with the most recent systemic cancer therapy regimen and prior to signature of the tissue ICF (ARCHIVAL PRETREATMENT sample).\n\n      OR\n   2. Newly obtained pretreatment tumor biopsy from ≥1 lesion not previously irradiated and amenable to sampling, after signature of tissue ICF (FRESH PRETREATMENT sample)\n6. Has Eastern Cooperative Oncology Group performance status (ECOG PS) of 0 or 1 at screening.\n\nExclusion Criteria\n\nParticipants who meet any of the following criteria will be disqualified from entering the study:\n\n1. Has HER2-positive gastric cancer as classified by ASCO-CAP guidelines and determined prior to enrollment by assessment in a local laboratory that is Clinical Laboratory Improvement Amendments certified (US sites) or accredited based on specific country regulations.\n2. Has nasopharyngeal cancer.\n3. Has mucosal or uveal melanoma.\n4. Has a history of (non-infectious) interstitial lung disease (ILD), that required corticosteroids, has current ILD\u002Fpneumonitis, or suspected ILD\u002Fpneumonitis cannot be ruled out by imaging at screening.\n5. Has clinically severe respiratory compromise (based on the investigator's assessment) resulting from intercurrent pulmonary illnesses\n6. Is receiving chronic systemic corticosteroids dosed at \\>10 mg prednisone daily or equivalent anti-inflammatory activity or any form of immunosuppressive therapy prior to Cycle 1 Day 1.\n\n   Participants who require use of bronchodilators, inhaled or topical steroids, or local steroid injections may be included in the study.\n7. Had prior treatment with an anti-HER3 antibody and\u002For antibody-drug conjugate (ADC) that consists of an exatecan derivative that is a topoisomerase I inhibitor (eg, trastuzumab deruxtecan).\n8. Has history of other active malignancy within 3 years prior to Cycle 1 Day 1, except the following:\n\n   1. Adequately treated nonmelanoma skin cancer\n   2. Adequately treated intraepithelial carcinoma of the cervix\n   3. Any other curatively treated in situ disease\n9. Has any evidence of severe or uncontrolled diseases (eg, active bleeding diatheses, active serious infection) psychiatric illness\u002Fsocial situations, geographical factors, substance abuse, or other factors that, in the investigator's opinion, make it high risk for the subject to participate in the study or that would jeopardize compliance with the protocol\n10. Has previously received topoisomerase-1 inhibitors (e.g., irinotecan) treatment in the advanced or metastatic disease setting.",{"count":228,"type":23},740,[27],"This is a proof-of-concept study designed to investigate HER3-DXd monotherapy in locally advanced unresectable or metastatic solid tumors. The study is enrolling cohorts of participants with melanoma \\[cutaneous\u002Facral\\], squamous cell carcinomas of the head and neck (SCCHN), HER2-negative gastric cancer ovarian carcinoma, cervical cancer, endometrial cancer, bladder cancer, esophageal carcinoma, pancreatic carcinoma, prostate cancer, second-line gastric cancer, lung cancer, and breast cancer.",[232,233,234,235,236,79,32,153,237,238,155,239,154,152],"Advanced Solid Tumor","Melanoma","Head and Neck Cancer","Gastric Cancer","Ovarian Carcinoma","Esophageal Cancer","Pancreatic Carcinoma","Non-small Cell Lung Cancer (NSCLC)",[232,233,234,235,241,242,243,244,245,246,247,248,249,250,154,152],"Ovarian carcinoma","Cervical cancer","Endometrial cancer","Bladder cancer","Esophageal carcinoma","Pancreatic carcinoma","Prostate cancer","Patritumab Deruxtecan","HER3-DXd","U3-1402",{"date":50,"type":51},{"date":253,"type":51},"2024-02-26",{"date":255,"type":23},"2028-10-10",{"name":257,"class":58},"Daiichi Sankyo",86,{"id":260,"slug":261,"hasResults":12,"nctId":262,"briefTitle":263,"officialTitle":264,"acronym":265,"eligibilityCriteria":266,"healthyVolunteers":12,"sex":110,"minAge":19,"maxAge":267,"enrollmentInfo":268,"targetDuration":4,"studyType":24,"phases":269,"briefSummary":270,"conditions":271,"keywords":276,"overallStatus":47,"whyStopped":4,"lastUpdateSubmitDate":281,"lastUpdatePostDateStruct":282,"startDateStruct":283,"completionDateStruct":285,"leadSponsor":287,"locationsCount":171},"100652924","pelvic-ultra-hypofractionated-adjuvant-radiotherapy-for-endometrial-cancer-pure-cohort-100652924","NCT07779109","Pelvic Ultra-Hypofractionated Adjuvant Radiotherapy for Endometrial Cancer (PURE-cohort)","Pelvic Ultra-Hypofractionated Adjuvant Radiotherapy for High-Intermediate and High-Risk Endometrial Cancer: A Prospective Multicenter Phase II Safety Cohort Study","PURE-cohort","Inclusion Criteria:\n\n1. Aged \\> 18 years.\n2. Histologically confirmed diagnosis of endometrial cancer post hysterectomy: endometrial adenocarcinoma, serous or clear cell carcinoma, or carcinosarcoma or dedifferentiated carcinoma.\n3. Patients candidates for adjuvant pelvic (Cht)EBRT treatment (+\u002F- vaginal cuff brachytherapy), categorized by Intermediate-high risk and high risk primary endometrial cancer based on recent ESGO\u002FESTRO\u002FESMO Guidelines (2025).\n4. Patient is willing and able to give informed consent to participate in this clinical trial.\n5. Patient must be willing and able to complete the QLQ-C30 questionnaire with EN-24 companion as described in the study protocol\n6. Possibility of fiducial marker placement on vaginal vault.\n7. Dosimetric feasibility based on OAR constraint and targets objective\n\nExclusion Criteria:\n\n1. Prior pelvic or abdominal radiation therapy delivered.\n2. Inflamatory bowel disease of other contraindication to pelvic radiotherapy.\n3. Previous abdominal or pelvic complicated surgery.","110 Years",{"count":147,"type":23},[149],"The PURE trial is a prospective multicenter phase II study evaluating the safety and feasibility of ultra-hypofractionated adjuvant pelvic radiotherapy in patients with high-intermediate-risk and high-risk endometrial cancer following surgery. The study investigates a treatment regimen consisting of 27.5 Gy delivered in five fractions using modern image-guided IMRT\u002FVMAT techniques. The primary objective is to assess acute gastrointestinal and genitourinary toxicity according to CTCAE version 5.0.",[272,273,32,274,275],"SBRT","Radiation Therapy","Endometrial Cancer Stage III","High-risk Endometrial Cancer",[243,277,278,279,280],"Ultrahypofractionated Radiation Therapy","Postoperative pelvic radiation therapy","Postoperative pelvic sbrt","high-risk endometrial cancer","2026-08-18",{"date":50,"type":51},{"date":284,"type":51},"2026-03-30",{"date":286,"type":23},"2035-03-30",{"name":288,"class":170},"Instituto de Investigación Sanitaria Aragón",{"id":290,"slug":291,"hasResults":12,"nctId":292,"briefTitle":293,"officialTitle":294,"acronym":295,"eligibilityCriteria":296,"healthyVolunteers":12,"sex":110,"minAge":19,"maxAge":4,"enrollmentInfo":297,"targetDuration":4,"studyType":24,"phases":298,"briefSummary":299,"conditions":300,"keywords":301,"overallStatus":47,"whyStopped":4,"lastUpdateSubmitDate":281,"lastUpdatePostDateStruct":304,"startDateStruct":305,"completionDateStruct":307,"leadSponsor":309,"locationsCount":171},"100557455","hypofractionated-external-beam-radiotherapy-with-adaptive-planning-for-endometrial-and-cervical-cancers-100557455","NCT06538337","Hypofractionated External Beam Radiotherapy With Adaptive Planning for Endometrial and Cervical Cancers","Hypofractionated External Beam Radiotherapy With Adaptive Planning for Endometrial and Cervical Cancers (HERA Trial)","HERA","Inclusion Criteria:\n\n* Histologically confirmed endometrial or cervical cancer\n* Surgical resection of the primary tumor\n* International Federation of Gynecology and Obstetrics (FIGO) Stage IA-IVB endometrial cancer OR FIGO Stage IA-IIA cervical cancer that meets indications for receiving adjuvant pelvic radiotherapy alone as standard of care\n* Age ≥ 18 years old\n* Karnofsky performance status (KPS) ≥ 60 or Eastern Cooperative Oncology Group (ECOG) 0-2\n\nExclusion Criteria:\n\n* Must not meet indications for receiving concurrent chemotherapy as standard of care\n* Active treatment of a separate malignancy\n* History of prior irradiation to the area to be treated",{"count":59,"type":23},[149],"After surgery to remove the main endometrial and\u002For cervical tumor, most women receive radiation therapy. This study uses hypo-fractionated radiation therapy, which is a type of radiation therapy in which the total prescribed dose of radiation is delivered in fewer but larger doses than conventional or standard radiotherapy.\n\nThis research study aims to determine if hypo-fractionated radiation therapy given after surgery can improve treatment tolerability (i.e., fewer treatments) with comparable side effects.\n\nParticipants will be in the study for about 5 years:\n\nRadiation therapy:\n\n* 5 daily treatment sessions of MRI or CT-Guided Stereotactic Body Radiation Therapy (SBRT).\n* Each treatment session will occur on a weekday (typically consecutive weekdays) and will last approximately an hour.\n\nTreatment Follow-Up:\n\n* Check-up Appointment and answer questions at 3 months post RT\n* Check-up Appointments with physical exam every 6 months (+\u002F- 4 weeks) for up to 5 years.",[32,79],[302,303,272],"endometrial","cervical",{"date":48,"type":51},{"date":306,"type":51},"2024-07-24",{"date":308,"type":23},"2032-07-26",{"name":310,"class":170},"Jonsson Comprehensive Cancer Center",{"id":312,"slug":313,"hasResults":12,"nctId":314,"briefTitle":315,"officialTitle":316,"acronym":4,"eligibilityCriteria":317,"healthyVolunteers":12,"sex":110,"minAge":19,"maxAge":4,"enrollmentInfo":318,"targetDuration":4,"studyType":24,"phases":320,"briefSummary":321,"conditions":322,"keywords":325,"overallStatus":47,"whyStopped":4,"lastUpdateSubmitDate":281,"lastUpdatePostDateStruct":330,"startDateStruct":331,"completionDateStruct":333,"leadSponsor":335,"locationsCount":337},"100407815","phase-1-a-study-to-find-out-how-safe-regn5668-is-and-how-well-it-works-in-adult-women-when-given-with-either-cemiplimab-or-cemiplimab--fianlimab-or-ubamatamab-100407815","NCT04590326","A Study to Find Out How Safe REGN5668 is and How Well it Works In Adult Women When Given With Either Cemiplimab, or Cemiplimab + Fianlimab, or Ubamatamab","A Phase 1\u002F2 Study of REGN5668 (MUC16xCD28, a Costimulatory Bispecific Antibody) Administered in Combination With Other Agents in MUC16 + Malignancies","Key Inclusion Criteria:\n\n1. Ovarian Cancer Cohorts Only: Has histologically or cytologically confirmed diagnosis of advanced epithelial ovarian cancer (except carcinosarcoma), primary peritoneal, or fallopian tube cancer that has received at least 1 line of platinum-based systemic therapy as defined in the protocol\n2. Expansion cohorts only: Has at least 1 lesion that is measurable by RECIST 1.1 as described in the protocol.\n3. Has a serum CA-125 level ≥2x ULN (in screening, not applicable to endometrial cohorts)\n4. Has adequate organ and bone marrow function as defined in the protocol\n5. Has an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.\n6. Has a life expectancy of at least 3 months\n7. Endometrial Cancer Cohorts Only: histologically confirmed endometrial cancer that has progressed or recurrent after prior anti-PD-1 therapy and platinum-based chemotherapy as described in the protocol\n\nKey Exclusion Criteria:\n\n1. Current or recent (as defined in the protocol) treatment with an investigational agent, systemic biologic therapy, or anti-cancer immunotherapy\n2. Has had another malignancy within the last 5 years that is progressing, requires active treatment, or has a high likelihood of recurrence as defined in the protocol\n3. Prior treatment with a Mucin 16 (MUC16)-targeted therapy\n4. Ovarian Expansion cohorts only: More than 5 prior lines of systemic therapy\n5. Has any condition that requires ongoing\u002Fcontinuous corticosteroid therapy as defined in the protocol within 1 week prior to the first dose of study drug\n6. Has ongoing or recent (within 5 years) evidence of significant autoimmune disease that required treatment with systemic immunosuppressive treatments as defined in the protocol\n7. Has untreated or active primary brain tumor, CNS metastases, leptomeningeal disease, or spinal cord compression as defined in the protocol\n8. Has history of clinically significant cardiovascular disease as defined in the protocol\n9. Has known allergy or hypersensitivity to cemiplimab and\u002For components of study drug(s).\n\nNote: Other protocol-defined Inclusion\u002FExclusion criteria apply",{"count":319,"type":23},612,[26,27],"This study is researching an investigational drug called REGN5668 :\n\n* alone or,\n* combined with cemiplimab (also known as REGN2810) or,\n* combined with both cemiplimab and fianlimab (also known as REGN3767), or\n* combined with ubamatamab (also known as REGN4018), with or without sarilumab.\n\nThe main purposes of this study are to:\n\n* Learn about the safety and profile of any side effects from the study drugs and to determine the highest, safe dose that can be given to participants with ovarian cancer or cancer of the uterus\n* Look for signs that the study drugs can treat ovarian cancer or cancer of the uterus\n\nThis study has 2 parts. The purpose of Part 1 (Escalation) is to find the highest, safe dose of the study drug(s). The purpose of Part 2 (Expansion) is to use the doses chosen in Part 1. Participants with cancer of the uterus will only participate in Part 2.\n\nThe study is looking at several other research questions, including:\n\n* Side effects that may be experienced by participants taking REGN5668 alone and\u002For in combination with cemiplimab, cemiplimab and fianlimab, or ubamatamab\n* How REGN5668 works in the body either alone and\u002For in combination with cemiplimab, cemiplimab and fianlimab, or ubamatamab\n* How much of the study drugs (REGN5668, cemiplimab, fianlimab, ubamatamab) are in the blood\n* To see if REGN5668 in combination with cemiplimab, cemiplimab and fianlimab, or ubamatamab works to treat cancer",[30,323,324,32],"Fallopian Tube Cancer","Primary Peritoneal Cancer",[326,327,328,329],"Progressive","Recurrent","Refractory","Serum CA-125 levels >= 2x ULN",{"date":48,"type":51},{"date":332,"type":51},"2020-12-08",{"date":334,"type":23},"2027-11-30",{"name":336,"class":58},"Regeneron Pharmaceuticals",28,{"id":339,"slug":340,"hasResults":12,"nctId":341,"briefTitle":342,"officialTitle":343,"acronym":4,"eligibilityCriteria":344,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":345,"targetDuration":4,"studyType":24,"phases":347,"briefSummary":348,"conditions":349,"keywords":356,"overallStatus":47,"whyStopped":4,"lastUpdateSubmitDate":281,"lastUpdatePostDateStruct":378,"startDateStruct":379,"completionDateStruct":381,"leadSponsor":383,"locationsCount":385},"100370548","phase-1-a-study-of-tulmimetostat-dzr123-cpi-0209-in-patients-with-advanced-solid-tumors-and-lymphomas-100370548","NCT04104776","A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas","A Phase 1\u002F2 Study of DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas","Key Inclusion Criteria:\n\nAll Patients:\n\n* Adults aged ≥18 years with life expectancy ≥12 weeks\n* ECOG performance status 0-1\n* Adequate recovery from prior therapy-related toxicities (Grade ≤1, with exceptions)\n* Adequate bone marrow, renal, and hepatic function per protocol-defined thresholds\n* Willingness to provide tumor tissue and blood samples for biomarker analyses\n* Agreement to protocol-specified contraception requirements\n* Signed informed consent prior to study procedures\n\nDisease-Specific Inclusion Criteria:\n\nPhase 1 (Dose Escalation):\n\n* Histologically or cytologically confirmed locally advanced or metastatic solid tumors or lymphoma\n* Disease refractory to standard therapy or with no available effective standard treatment\n* For prostate cancer: castrate testosterone levels maintained throughout the study\n\nPhase 2 (Disease-Specific Cohorts):\n\n* M1: ARID1A mutant urothelial carcinoma or other ARID1A mutant solid tumors (with cohort specific prior therapy and RECIST 1.1 measurable disease requirements)\n* M2: ARID1A mutant ovarian clear cell carcinoma after prior platinum-based therapy (and bevacizumab unless contraindicated)\n* M3: ARID1A mutant recurrent\u002Fmetastatic endometrial carcinoma after platinum therapy and appropriate immunotherapy\n* M4: Relapsed\u002Frefractory peripheral T cell lymphoma or diffuse large B cell lymphoma, transplant-ineligible, with measurable disease\n* M5: Relapsed\u002Frefractory pleural or peritoneal mesothelioma with documented BAP1 loss\n* M6: Metastatic castration-resistant prostate cancer (mCRPC) with documented progression after AR targeted therapy and taxane chemotherapy\n* M7: ARID1A wild type endometrial carcinoma (exploratory food-effect cohort)\n* M8: mCRPC treated with DZR123 in combination with enzalutamide, with cohort specific requirements for prior androgen receptor pathway inhibitor and chemotherapy exposure\n\nKey Exclusion Criteria:\n\nAll Patients:\n\nMedical Conditions:\n\n* Prior solid organ or allogeneic hematopoietic cell transplant\n* Active or untreated symptomatic CNS metastases (with limited exceptions)\n* Clinically significant cardiovascular disease, including uncontrolled arrhythmias or prolonged QTc\n* Active interstitial lung disease or pneumonitis\n* Uncontrolled infections or significant gastrointestinal disorders affecting absorption\n* Active HIV or hepatitis B\u002FC infection\n* Concurrent malignancy requiring active treatment (with protocol-defined exceptions)\n* Pregnancy, breastfeeding, or inability to comply with protocol requirements\n\nPrior or Concomitant Therapy:\n\n* Recent anticancer therapy within protocol-defined washout periods\n* Prior EZH2 inhibitor treatment\n* Recent radiation or liver-directed therapies outside allowed windows\n* Use of strong CYP3A4\u002F5 inhibitors or inducers\n\nAdditional Cohort-Specific Exclusions:\n\n* M6 (mCRPC): Bone-only disease, unstable bone lesions, PSA-lowering herbal products, recent prohibited prostate cancer therapies\n* M8 (Combination): PSA-only disease, prior investigational androgen receptor pathway inhibitors, significant seizure risk, extensive prior bone marrow irradiation, active inflammatory gastrointestinal disease",{"count":346,"type":23},300,[26,27],"The purpose of this open-label, first-in-human (FIH) trial is to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary antitumor activity of DZR123 (Tulmimetostat, CPI-0209), both as monotherapy and in combination with enzalutamide, in patients with advanced solid tumors and lymphomas.",[232,350,351,352,353,32,354,355],"Diffuse Large B Cell Lymphoma","Lymphoma, T-Cell","Mesothelioma, Malignant","Prostatic Neoplasms, Castration-Resistant","Ovarian Clear Cell Carcinoma","Metastatic Castration-resistant Prostate Cancer",[357,358,359,360,361,362,363,364,365,366,367,368,369,370,371,372,373,32,354,374,375,376,377],"Tulmimetostat","DZR123","Lymphoma, Large B-Cell, Diffuse","Lymphoma, B-cell","Lymphoma, T-cell","Lymphoma, Non-Hodgkin","Lymphoma","Neoplasms by Site","Neoplasms by Histologic Type","Neoplasms","Lymphoproliferative Disorders","Lymphatic Diseases","Immunoproliferative Disorders","Immune System Diseases","Topoisomerase Inhibitors","Molecular Mechanisms of Pharmacological Action","Antineoplastic Agents","Food effect","Adenine-thymine (AT)-rich interactive domain-containing protein 1A (ARID1A)","ARID1A wildtype (ARID1A WT) endometrial carcinoma","Metastatic castration-resistant prostate cancer (mCRPC)",{"date":93,"type":51},{"date":380,"type":51},"2019-09-18",{"date":382,"type":23},"2030-02-27",{"name":384,"class":58},"Novartis Pharmaceuticals",80,{"id":387,"slug":388,"hasResults":12,"nctId":389,"briefTitle":390,"officialTitle":391,"acronym":4,"eligibilityCriteria":392,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":393,"targetDuration":4,"studyType":24,"phases":395,"briefSummary":396,"conditions":397,"keywords":400,"overallStatus":47,"whyStopped":4,"lastUpdateSubmitDate":405,"lastUpdatePostDateStruct":406,"startDateStruct":407,"completionDateStruct":409,"leadSponsor":411,"locationsCount":413},"100629146","phase-1-a-study-of-muc16-directed-antibody-drug-conjugate-hwk-016-in-participants-with-advanced-solid-tumors-100629146","NCT07470853","A Study of MUC16-Directed Antibody Drug Conjugate HWK-016 in Participants With Advanced Solid Tumors.","A Phase 1 First-in-Human Study of MUC16-Directed Antibody Drug Conjugate HWK-016 in Participants With Advanced Solid Tumors.","Inclusion Criteria:\n\n* Have one of the following solid tumor cancers:\n\n  1. Monotherapy escalation, backfill and expansion cohorts:\n\n     1. Endometrial Carcinoma\n     2. Ovarian Cancer\n  2. Combination Escalation, Backfill and Expansion Cohorts a. Ovarian Cancer\n\nExclusion Criteria:\n\n1. Individual with known or suspected uncontrolled central nervous system (CNS) metastases\n2. Individual with history of carcinomatous meningitis\n3. Individual with active uncontrolled systemic bacterial, viral, fungal, or parasitic infection\n4. Individual with evidence of corneal keratopathy or history of cornea transplant\n5. Any serious unresolved toxicities from prior therapy\n6. Significant cardiovascular disease\n7. Prolongation of QT interval corrected for heart rate using Fridericia's formula (QTcF) ≥ 470 milliseconds (ms)\n8. History of pneumonitis\u002Finterstitial lung disease\n9. Individuals who are pregnant, breastfeeding or plan to breastfeed during study or within 30 days of last dose of study intervention",{"count":394,"type":23},265,[26],"HWK-016-101 is a multicenter, open-label, first-in-human (FIH) Phase 1 study evaluating HWK-016, a targeted antibody-drug conjugate (ADC) in adult participants with advanced or metastatic solid tumors. The study employs a dose escalation and dose expansion design without a control group.\n\nThe study consists of 2 parts (Part A: monotherapy and Part B: combination therapy with bevacizumab); each part has 2 phases, Phase 1a (dose escalation) and Phase 1b (dose expansion). Enrollment to Part A (Phase 1a and Phase 1b) will include ovarian and endometrial cancers. Enrollment to Part B (Phase 1a and Phase 1b) will include ovarian cancer only. A subsequent protocol amendment may evaluate additional tumor types.",[398,399,32],"PROC","Platinum Resistant Ovarian Cancer",[30,32,398,401,402,35,403,404],"Ovarian","Endometrial","Phase 1","Solid tumor","2026-08-17",{"date":281,"type":51},{"date":408,"type":51},"2026-03-15",{"date":410,"type":23},"2028-02",{"name":412,"class":58},"Whitehawk Therapeutics, Inc.",12,{"id":415,"slug":416,"hasResults":12,"nctId":417,"briefTitle":418,"officialTitle":419,"acronym":4,"eligibilityCriteria":420,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":421,"targetDuration":4,"studyType":24,"phases":423,"briefSummary":424,"conditions":425,"keywords":432,"overallStatus":47,"whyStopped":4,"lastUpdateSubmitDate":405,"lastUpdatePostDateStruct":434,"startDateStruct":435,"completionDateStruct":437,"leadSponsor":439,"locationsCount":195},"100606945","phase-1-a-phase-1-study-of-nrm-823-in-participants-with-locally-advanced-or-metastatic-refractory-solid-tumors-100606945","NCT07182149","A Phase 1 Study of NRM-823 in Participants With Locally Advanced or Metastatic Refractory Solid Tumors","A Phase 1a\u002F1b Study of NRM-823 as Monotherapy and in Combination With Immune Checkpoint Inhibition in Participants With Locally Advanced or Metastatic Refractory Solid Tumors","Inclusion Criteria:\n\n* Have histologically- or cytologically-diagnosed NSCLC (squamous or adenocarcinoma), TNBC, HNSCC, ESCC, esophageal adenocarcinoma, gastric\u002FGEJ adenocarcinoma, cervical, endometrial, or ovarian cancer which is advanced or metastatic.\n* Have an Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1.\n* Adequate liver, renal, pulmonary, and cardiac function.\n* Adequate hematologic function.\n\nExclusion Criteria:\n\n* Has received cytotoxic chemotherapy, biologic anticancer agents, checkpoint inhibitors, or radiation therapy (excluding bone-only radiation therapy) ≤3 weeks or 5 half-lives (whichever is shorter) prior to the first dose of NRM-823\n* History of Grade 2 pneumonitis requiring steroids or any Grade 3 or 4 pneumonitis from any prior therapy.\n* Has received an investigational therapy \\\u003C4 weeks or 5 half-lives prior to the first dose of NRM823, whichever is shorter prior to the first dose of NRM-823.\n* With the exception of alopecia and Grade ≤2 neuropathy, any unresolved toxicities from prior therapy greater than CTCAE Grade 1 at the time of starting study drug.",{"count":422,"type":23},150,[26],"This study is being done to find out of NRM-823 is safe and can treat participants with locally advanced or metastatic solid tumors.",[426,427,428,429,430,30,87,79,32,431],"HNSCC","ESCC","Esophageal Adenocarcinoma","Gastric Adenocarcinoma","GEJ Adenocarcinoma","Triple Negative Breast Cancer (TNBC)",[433],"NRM-823",{"date":281,"type":51},{"date":436,"type":51},"2025-10-30",{"date":438,"type":23},"2028-10-31",{"name":440,"class":58},"Normunity AccelCo, Inc.",{"id":442,"slug":443,"hasResults":12,"nctId":444,"briefTitle":445,"officialTitle":446,"acronym":4,"eligibilityCriteria":447,"healthyVolunteers":12,"sex":110,"minAge":19,"maxAge":4,"enrollmentInfo":448,"targetDuration":4,"studyType":24,"phases":450,"briefSummary":452,"conditions":453,"keywords":455,"overallStatus":460,"whyStopped":4,"lastUpdateSubmitDate":461,"lastUpdatePostDateStruct":462,"startDateStruct":463,"completionDateStruct":465,"leadSponsor":467,"locationsCount":171},"100642707","phase-3-symbiotic-gyn-18-a-study-to-learn-about-the-study-medicine-called-pf-08634404-in-combination-with-chemotherapy-in-adult-participants-with-advanced-or-recurrent-mmr-proficient-endometrial-cancer-100642707","NCT07578649","Symbiotic-GYN-18: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Advanced or Recurrent MMR-proficient Endometrial Cancer","AN INTERVENTIONAL PHASE 3, OPEN LABEL, RANDOMIZED STUDY TO EVALUATE EFFICACY AND SAFETY OF PF-08634404 IN COMBINATION WITH CHEMOTHERAPY VERSUS PEMBROLIZUMAB IN COMBINATION WITH CHEMOTHERAPY IN ADULT PARTICIPANTS WITH ADVANCED OR RECURRENT MISMATCH REPAIR PROFICIENT ENDOMETRIAL CANCER","Inclusion Criteria:\n\n* Women ≥18 years of age who are confirmed not pregnant at screening.\n* Histologically or cytologically confirmed endometrial cancer that is recurrent or advanced; carcinosarcomas are eligible but pure sarcomas are excluded.\n* Newly diagnosed FIGO Stage III disease with measurable disease per RECIST v1.1, newly diagnosed FIGO Stage IV disease with or without measurable disease, or recurrent disease with or without measurable disease for which curative treatment with surgery and\u002For radiotherapy is unlikely.\n* For participants with recurrent disease, prior adjuvant systemic anti-cancer therapy is allowed if relapse occurred more than 6 months after the last dose.\n* Must provide tumor tissue for prospective central assessment of MMR and p53 status.\n* Proficient mismatch repair (pMMR) endometrial cancer as determined by central testing.\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1.\n* Life expectancy of at least 12 weeks.\n* Adequate organ function as defined in the protocol.\n\nExclusion Criteria:\n\n* Prior systemic therapy for first-line advanced or recurrent endometrial cancer.\n* Prior immunotherapy or anti-angiogenic therapy.\n* Deficient mismatch repair (dMMR) endometrial cancer by central testing.\n* Active or untreated central nervous system (CNS) metastases; participants with previously treated and clinically stable brain metastases may be eligible if not requiring steroids and without evidence of progression.\n* Clinically significant risk of bleeding or fistula, including a history of severe bleeding disorders.\n* History of another malignancy within 3 years, except for cancers with negligible risk of recurrence or death.\n* History of allogeneic organ or hematopoietic stem cell transplantation; active autoimmune disease requiring systemic treatment within the past 2 years; or history of immunodeficiency\n* Interstitial lung disease, pneumonitis, or clinically significant pulmonary disease\n* Uncontrolled or significant cardiovascular, metabolic, renal, hepatic, or vascular disease\n* Active or uncontrolled infection.\n* Recent major surgery or severe trauma within protocol-defined washout periods.",{"count":449,"type":23},600,[451],"PHASE3","This study is being conducted to assess whether the study medicine PF 08634404, given in combination with chemotherapy, improves outcomes compared with another medicine called pembrolizumab plus chemotherapy. Chemotherapy is a type of cancer treatment that uses medicines to destroy cancer cells or stop them from growing.\n\nOur bodies have a built-in DNA \"spell-checker,\" called the mismatch repair (MMR) system, that fixes genetic mistakes. In most endometrial cancers, this system works normally, and these cancers are called MMR-proficient (pMMR). However, pMMR tumors are harder for the immune system to recognize and attack. When endometrial cancer has spread beyond the uterus or comes back after previous treatment, it is called advanced or recurrent endometrial cancer. This study is for adults with mismatch repair-pMMR advanced or recurrent endometrial cancer.\n\nParticipants must meet key criteria, including:\n\n* Women who are 18 years or older, and not pregnant at the time of joining the study\n* pMMR endometrial cancer only\n* Measurable Stage III disease, Stage IV disease (with or without measurable disease) per FIGO staging, a system doctors use to describe how far cancer has spread in the body, or recurrent (with or without measurable disease) endometrial cancer\n* Has not received chemotherapy except for chemotherapy given after the main surgery and more than 6 months before relapse\n* Be in good enough health to receive study treatment. Approximately 600 adult women will be enrolled. Each participant will be randomly assigned (like a flip of the coin) to one of two treatment groups, with about half in each group. The study is open, meaning both the doctors and participants know what treatment is being given. Participants will receive their assigned treatment through intravenous infusions (medicine is given directly into a vein). The treatment will be given in cycles.\n\nExperimental Group will receive new study medicine called PF-08634404 plus chemotherapy. It will be followed by PF 08634404 alone for up to 2 years (35 cycles).\n\nControl Group will receive an approved medicine called pembrolizumab plus chemotherapy. It will be followed by pembrolizumab alone for up to 2 years (20 cycles).\n\nThe study will include regular visits for:\n\n* Participants will have regular visits to the study site for treatment, health checks, and tests.\n* After stopping treatment, participants will come for a final visit within a month to check their health and review any reactions.\n* Follow-up will continue every 12 weeks by phone or in person or by reviewing health records. This helps check health and any new treatments.\n* Tests will be done every 9 weeks during the first 104 weeks to see how the cancer is responding. After that, tests will be done every 12 weeks.",[454,32],"Endometrial Neoplasms",[456,454,457,458,459],"Recurrent Endometrial Carcinoma","Advanced Endometrial Carcinoma","Advanced or Recurrent Endometrial Cancer","pMMR","NOT_YET_RECRUITING","2026-08-14",{"date":405,"type":51},{"date":464,"type":23},"2026-10-09",{"date":466,"type":23},"2031-01-30",{"name":468,"class":58},"Pfizer",{"id":470,"slug":471,"hasResults":12,"nctId":472,"briefTitle":473,"officialTitle":474,"acronym":475,"eligibilityCriteria":476,"healthyVolunteers":12,"sex":110,"minAge":19,"maxAge":4,"enrollmentInfo":477,"targetDuration":4,"studyType":24,"phases":479,"briefSummary":480,"conditions":481,"keywords":4,"overallStatus":47,"whyStopped":4,"lastUpdateSubmitDate":461,"lastUpdatePostDateStruct":483,"startDateStruct":484,"completionDateStruct":486,"leadSponsor":488,"locationsCount":490},"100605713","phase-3-study-to-assess-the-efficacy-and-safety-of-rina-s-compared-to-treatment-of-investigators-choice-in-participants-with-endometrial-cancer-100605713","NCT07166094","Study to Assess the Efficacy and Safety of Rina-S Compared to Treatment of Investigator's Choice in Participants With Endometrial Cancer","A Phase 3 Randomized, Open-label Study of Rinatabart Sesutecan (Rina-S) Versus Treatment of Investigator's Choice (IC) in Patients With Endometrial Cancer After Platinum-Based Chemotherapy and PD(L)-1 Therapy","RAINFOL-03","Key Inclusion Criteria\n\n* Participants must have histologically or cytologically confirmed recurrent or progressive endometrial cancer (EC; any subtype excluding neuroendocrine tumors, carcinosarcoma, or endometrial sarcoma) following prior therapy.\n* Participants must have received at least 1, but not more than 3, prior lines of therapy:\n\n  * Participants must have received prior platinum-based chemotherapy and a programmed death (ligand)-1 (PD(L)-1) inhibitor, either separately or in combination\n  * If the tumor recurred more than 12 months after completion of platinum-based chemotherapy, additional platinum-based chemotherapy must be administered for recurrent disease unless the participant is ineligible for further platinum-based chemotherapy, in which case the reason for ineligibility must be documented.\n\n    * Note: If Immunotherapy-based treatment is administered in the advanced\u002Frecurrent setting, then platinum rechallenge is not required, regardless of the duration of the platinum-free interval from prior platinum-based chemotherapy. In such cases, the reason for ineligibility for platinum-based chemotherapy must be documented.\n  * Prior induction plus maintenance is considered 1 line of therapy\n  * Hormonal therapy alone (i.e., without chemotherapy) will not be counted as a separate line of therapy.\n  * Therapy changed due to toxicity in the absence of progression will be considered part of the same line of therapy (i.e., will not be counted independently as a separate line of therapy)\n* Participants must have progressed radiographically on or after their most recent line of therapy\n\nKey Exclusion Criteria\n\n* Prior therapy with an antibody-drug conjugate containing a topoisomerase 1 inhibitor.\n* Has a past or current malignancy other than the inclusion diagnosis before the planned first dose of study drug, or any evidence of residual disease from a previously diagnosed malignancy. Exceptions are malignancies with a negligible risk of metastasis or death (e.g., 5-year OS ≥90%), including, but not limited to, adequately treated cervical carcinoma of Stage 1B or less, noninvasive basal cell or squamous cell skin carcinoma, noninvasive superficial bladder cancer, ductal carcinoma in situ, or any past malignancy considered cured for ≥3 years (i.e., eligible participants must have complete response of ≥3 years duration).\n* Known active central nervous system metastases or carcinomatous meningitis. Participants with previously treated brain metastases may participate provided they are clinically stable for at least 4 weeks prior to study entry after completion of brain metastasis treatment, they have no new or enlarging brain metastases, and are off corticosteroids and anticonvulsants prescribed for symptoms associated with brain metastases for at least 7 days prior to the planned first dose of study drug. Participants with suspected brain metastases at screening should undergo a computed tomography (CT)\u002Fmagnetic resonance imaging (MRI) of the brain prior to study entry.\n* Hospitalization or clinical symptoms due to gastrointestinal obstruction within the past or radiographic evidence of gastrointestinal obstruction at the time of screening. Enrollment of participants who currently require parenteral nutrition must be discussed with the study medical monitor to determine eligibility.\n\nNote: Other protocol-defined Inclusion and Exclusion criteria may apply.",{"count":478,"type":23},660,[451],"The purpose of this study is to compare how well Rina-S (GEN1184) works compared to treatment of physician's choice (paclitaxel or doxorubicin) that are considered standard medical care for the treatment of recurrent or progressive endometrial cancer (EC) following prior therapy. There is an equal (50:50) chance of getting either Rina-S or a chemotherapy agent as treatment in this study.\n\nThe study duration will be approximately 3 years. The treatment duration will be different for every participant, but an average of 4 to 6 months is expected.\n\nAll participants will receive active drug; no one will be given placebo. Participation in the study will require visits to the study site(s).",[32,482],"Recurrent or Progressive Endometrial Cancer",{"date":405,"type":51},{"date":485,"type":51},"2025-11-28",{"date":487,"type":23},"2029-11",{"name":489,"class":58},"Genmab",160,{"id":492,"slug":493,"hasResults":12,"nctId":494,"briefTitle":495,"officialTitle":496,"acronym":4,"eligibilityCriteria":497,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":20,"enrollmentInfo":498,"targetDuration":4,"studyType":24,"phases":500,"briefSummary":501,"conditions":502,"keywords":504,"overallStatus":47,"whyStopped":4,"lastUpdateSubmitDate":510,"lastUpdatePostDateStruct":511,"startDateStruct":513,"completionDateStruct":515,"leadSponsor":517,"locationsCount":518},"100476843","phase-2-study-of-dato-dxd-as-monotherapy-and-in-combination-with-anti-cancer-agents-in-patients-with-advanced-solid-tumours-tropion-pantumor03-100476843","NCT05489211","Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)","A Phase II, Multicentre, Open-label, Master Protocol to Evaluate the Efficacy and Safety of Datopotamab Deruxtecan (Dato-DXd) as Monotherapy and in Combination With Anticancer Agents in Patients With Advanced\u002FMetastatic Solid Tumours","Key Inclusion Criteria: There are additional substudy requirements not reflected here. This list is based solely on the master CSP\n\n* Male and female, ≥ 18 years\n* Documented advanced or metastatic malignancy\n* Eastern Cooperative Oncology Group performance status of 0 or 1 with no deterioration over the 2 weeks prior to baseline or day of first dosing\n* All participants must provide a tumour sample for tissue-based analysis\n* At least 1 measurable lesion not previously irradiated, except Substudy 3 (Prostate Cancer) which allows participants with non measurable bone metastatic disease\n* Adequate bone marrow reserve and organ function\n* Minimum life expectancy of 12 weeks\n* At the time of screening, contraceptive use by men or women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies\n* All women of childbearing potential must have a negative serum pregnancy test documented during screening\n* Female participants must be 1 year post-menopausal, surgically sterile, or using 1 highly effective form of birth control. Female participants must not donate, or retrieve for their own use, ova at any time during this study\n* Male participants who intend to be sexually active with a female partner of childbearing potential must be surgically sterile, avoid intercourse, or use a highly effective method of contraception. Male participants must not freeze or donate sperm at any time during this study.\n* Capable of giving signed informed consent\n* Provision of signed and dated written optional genetic research informed consent prior to collection of samples for optional genetic research that supports the Genomic Initiative\n\nKey Exclusion Criteria:\n\n* Any evidence of diseases which, in the investigator's opinion, makes it undesirable for the participant to participate in the study or that would jeopardize compliance with the protocol\n* History of another primary malignancy except for adequately resected basal cell carcinoma or in situ squamous cell carcinoma of the skin, or other solid malignancy treated with curative intent\n* Persistent toxicities caused by previous anticancer therapy, excluding alopecia, not yet improved\n* Irreversible toxicity that is not reasonably expected to be exacerbated by study intervention in the opinion of the investigator, for example hearing loss\n* Spinal cord compression or brain metastases unless treated\n* Leptomeningeal carcinomatosis\n* Clinically significant corneal disease\n* Active hepatitis or uncontrolled hepatitis B or C virus infection\n* Uncontrolled infection requiring IV antibiotics, antivirals or antifungals, for example prodromal symptoms\n* Known HIV infection that is not well controlled\n* Known active tuberculosis infection\n* Mean resting corrected QTcF \\> 470 ms\n* In the judgement of the investigator, history of QT prolongation associated with other medications that required discontinuation of that medication, or any current concomitant medication known to prolong the QT interval and cause TdP\n* In the judgement of the investigator, congenital long QT syndrome, family history of long QT syndrome, or unexplained sudden death under 40 years of age in first-degree relatives\n* Uncontrolled or significant cardiac diseases\n* History of non-infectious Interstitial lung disease (ILD)\u002Fpneumonitis, including radiation pneumonitis that required steroids\n* Has severe pulmonary function compromise\n* Prior exposure to chloroquine\u002Fhydroxychloroquine without an adequate treatment washout period\n* Receipt of live, attenuated vaccine within 30 days prior to the first dose of study intervention\n* Prior exposure to anticancer therapies without an adequate treatment washout period prior to enrolment or any concurrent anticancer treatment\n* Palliative radiotherapy with a limited field of radiation within ≤ 2 weeks or to more than 30% of the bone marrow within ≤ 4 weeks before the first dose of study intervention\n* Major surgical procedure or significant traumatic injury within ≤ 3 weeks of the first dose of study intervention or an anticipated need for major surgery during the study\n* Prior treatment with TROP2-directed therapies or other antibody-drug conjugate (ADCs) with deruxtecan payload\n* Herbal or natural products intended as treatment or prophylaxis for any type of cancer that may interfere with the activity of the study intervention\n* Previous treatment in the present study\n* Participation in another clinical study with a study intervention or investigational medicinal device administered in the last 4 weeks prior to first dose of study intervention or concurrent enrolment in another clinical study\n* Severe hypersensitivity to Dato-DXd or any of the excipients, including but not limited to polysorbate 80 or other monoclonal antibodies\n* Involvement in the planning and\u002For conduct of the study\n* Judgment by the investigator that the participant should not participate in the study if the participant is unlikely to comply with study procedures, restrictions, and requirements\n* Females that are pregnant, breastfeeding, or planning to become pregnant\n* Female participants should refrain from breastfeeding from enrolment throughout the study and for at least 7 months after last dose of Dato-DXd",{"count":499,"type":23},454,[27],"TROPION-PanTumor03 will investigate the safety, tolerability, and anti-tumour activity of Datopotamab Deruxtecan (Dato-DXd) as Monotherapy and in Combination with Anticancer Agents in Patients with Advanced\u002FMetastatic Solid Tumours.",[32,235,355,30,76,503,209],"Urothelial Cancer",[505,506,507,508,509],"TROPION-PanTumor03","Datopotamab Deruxtecan (Dato-DXd)","Solid Tumours","Antibody-drug conjugate (ADC)","Trophoblast cell surface protein 2 (TROP2)","2026-08-12",{"date":512,"type":51},"2026-08-13",{"date":514,"type":51},"2022-09-06",{"date":516,"type":23},"2027-10-01",{"name":57,"class":58},96,{"id":520,"slug":521,"hasResults":12,"nctId":522,"briefTitle":523,"officialTitle":523,"acronym":4,"eligibilityCriteria":524,"healthyVolunteers":12,"sex":110,"minAge":19,"maxAge":4,"enrollmentInfo":525,"targetDuration":4,"studyType":113,"phases":4,"briefSummary":527,"conditions":528,"keywords":4,"overallStatus":47,"whyStopped":4,"lastUpdateSubmitDate":532,"lastUpdatePostDateStruct":533,"startDateStruct":534,"completionDateStruct":536,"leadSponsor":538,"locationsCount":540},"100622358","development-of-a-shared-decision-tool-to-facilitate-uptake-of-the-levonorgestrel-releasing-intrauterine-system-for-the-primary-prevention-of-endometrial-cancer-100622358","NCT07382583","Development of a Shared Decision Tool to Facilitate Uptake of the Levonorgestrel-releasing Intrauterine System for the Primary Prevention of Endometrial Cancer","This study will include participants from three categories: Unaffected women, Affected women, and Healthcare Providers. The eligibility criteria for each group are listed below:\n\nInclusion Criteria:\n\n1. Unaffected women\n\n   1. Must be at least 18 years old\n   2. Must read and speak English or Spanish\n   3. Must be premenopausal\n   4. Must not have a prior history of EC or complex atypical hyperplasia\n   5. Must provide written, informed consent\n   6. No physical, psychological, or cognitive impairments that would preclude participation in an interview as determined by the PI or study team member\n2. Affected women\n\n   1. Must be at least 18 years old\n   2. Must read and speak English or Spanish\n   3. Must have a prior history of EC or complex atypical hyperplasia\n   4. Must provide written, informed consent\n   5. No physical, psychological, or cognitive impairments that would preclude participation in an interview as determined by the PI or study team member\n3. Healthcare Providers\n\n   1. Physicians or advanced practice providers (physician assistants, nurse practitioners) from Family Medicine, Obstetrics \\& Gynecology, Internal Medicine, or Endocrinology\n   2. Must be at least 18 years old\n   3. Must read and speak English or Spanish\n   4. Must provide written, informed consent for qualitative interviews\n\nExclusion Criteria:\n\n* N\u002FA",{"count":526,"type":23},270,"To develop an educational tool to help patients and healthcare professionals make informed decisions about endometrial cancer and available prevention options for it (such as the use of a levonorgestrel-releasing intrauterine system \\[LNG-IUS\\]).",[529,530,531,32],"Levonorgestrel","Intrauterine Systems","Prevention","2026-08-11",{"date":510,"type":51},{"date":535,"type":51},"2026-02-12",{"date":537,"type":23},"2030-02-01",{"name":539,"class":170},"M.D. Anderson Cancer Center",2,{"id":542,"slug":543,"hasResults":12,"nctId":544,"briefTitle":545,"officialTitle":546,"acronym":4,"eligibilityCriteria":547,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":548,"targetDuration":4,"studyType":24,"phases":550,"briefSummary":551,"conditions":552,"keywords":4,"overallStatus":47,"whyStopped":4,"lastUpdateSubmitDate":532,"lastUpdatePostDateStruct":555,"startDateStruct":556,"completionDateStruct":558,"leadSponsor":560,"locationsCount":562},"100580714","phase-1-a-study-of-phst001-in-advanced-solid-tumors-100580714","NCT06840886","A Study of PHST001 in Advanced Solid Tumors","An Open-label, Phase 1a\u002F1b, Dose Escalation and Dose Expansion Study Investigating the Safety, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of PHST001 in Adult Patients With Advanced Relapsed and\u002For Refractory Solid Tumors","Key Inclusion Criteria:\n\n* Histologically or cytologically confirmed advanced solid tumor which has relapsed from or been refractory to all locally available standard therapies.\n* Adequate organ function per laboratory testing\n* Pregnancy prevention requirements\n* Measurable disease per RECIST v1.1 (or RANO) as assessed by the local site Investigator\u002Fradiology\n* Performance status of 0 or 1 on Eastern Cooperative Oncology Group (ECOG) scale\n\nKey Exclusion Criteria:\n\n* Diagnosis of immunodeficiency\n* History of a previous additional malignancy, unless potentially curative treatment has been completed, with no evidence of malignancy for 5 years. Participants with basal cell carcinoma of the skin, Stage I melanoma, melanoma in situ, squamous cell carcinoma of the skin, early-stage prostate cancer, or carcinoma in situ, excluding carcinoma in situ of the bladder, who have undergone potentially curative therapy are not excluded and can be enrolled regardless of disease-free period following completion of potentially curative therapy. Participants with early-stage breast cancer who have undergone curative intent treatment and with no disease recurrence for 2 years after treatment are not excluded.\n* Active known CNS metastases and\u002For carcinomatous meningitis. Participants with previously treated CNS metastases may participate provided they are radiologically stable (i.e., without evidence of progression for at least 2 weeks by repeat imaging \\[note that the repeat imaging should be performed during study screening\\]), clinically stable, and without requirement of steroid treatment for at least 14 days prior to the first dose of study treatment.\n* Received prior systemic anticancer therapy including investigational agents within 21 days or, if shorter, within 5 half-lives prior to the first dose of study treatment. Participants must have recovered from all AEs due to previous therapies to Grade ≤1 or baseline. Participants with Grade ≤2 neuropathy may be eligible. Participants with endocrine-related AEs Grade ≤2 requiring treatment or hormone replacement may be eligible.\n* Prior autologous or allogeneic hematopoietic stem cell transplant or solid organ transplant.\n* Received previous treatment with another agent targeting CD24.",{"count":549,"type":23},272,[26],"This is a multi-center, first-in-human (FIH), open-label, Phase 1a\u002F1b dose escalation and dose expansion study to assess the safety, PK, pharmacodynamics, and antitumor activity of PHST001 monotherapy (Phase 1a) or in combination with chemotherapy (Phase 1b) in adult participants with advanced relapsed and\u002For refractory solid tumors (including but not limited to CNS tumors in Phase 1a only). In Phase 1b cohort expansions, the study will focus on participants with advanced relapsed and\u002For refractory ovarian cancer, endometrial cancer, and cholangiocarcinoma. The study's primary objective is to evaluate the safety and tolerability of PHST001 and determine the RP2D (Recommended Phase 2 dose) of PHST001 monotherapy and in combination with chemotherapy as well as assess the anti-tumor activity of PHST001 and chemotherapy in Phase 1b.",[186,30,32,553,554],"Cholangiocarcinoma","CNS Tumor",{"date":510,"type":51},{"date":557,"type":51},"2025-03-31",{"date":559,"type":23},"2031-04",{"name":561,"class":58},"Pheast Therapeutics",20,{"id":564,"slug":565,"hasResults":12,"nctId":566,"briefTitle":567,"officialTitle":568,"acronym":4,"eligibilityCriteria":569,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":570,"targetDuration":4,"studyType":24,"phases":572,"briefSummary":573,"conditions":574,"keywords":577,"overallStatus":47,"whyStopped":4,"lastUpdateSubmitDate":532,"lastUpdatePostDateStruct":579,"startDateStruct":580,"completionDateStruct":582,"leadSponsor":584,"locationsCount":585},"100448747","phase-1-a-phase-iiia-study-of-azd8205-given-alone-or-combined-in-participants-with-advancedmetastatic-solid-malignancies-100448747","NCT05123482","A Phase I\u002FIIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced\u002FMetastatic Solid Malignancies","A Phase I\u002FIIa Multi-center, Open-label Master Protocol Dose Escalation and Expansion Study of AZD8205 as Monotherapy and in Combination With Anticancer Agents in Participants With Advanced Solid Tumors (BLUESTAR)","Key Inclusion Criteria:\n\n* Age ≥ 18 years\n* Relapsed\u002Fmetastatic solid tumors treated with prior adequate standard of care therapy for tumor type and stage of disease or where in the opinion of the Investigator, a clinical trial is the best option for the next treatment based on response and\u002For tolerability to prior therapy.\n* Measurable disease per RECIST v1.1\n* Eastern Cooperative Oncology Group (ECOG) Performance Status: 0-1\n* Life expectancy ≥ 12 weeks\n* Adequate bone marrow, hepatic, and renal function as defined in the protocol\n\nAdditional Inclusion Criteria For Sub-Study 1 Part A:\n\n• Histologically or cytologically confirmed metastatic or locally advanced\u002Frecurrent breast cancer, ovarian cancer, BTC or endometrial cancer\n\nAdditional Inclusion Criteria For Sub-Study 1 Part B:\n\n* Histologically or cytologically confirmed metastatic or locally advanced and recurrent disease for the respective cohort:\n\n  1. Cohort B1 (Biliary Tract Cancer)\n  2. Cohort B2 (Ovarian Cancer)\n  3. Cohort B3 (Breast Cancer)\n  4. Cohort B4 (Endometrial Cancer)\n  5. Cohort B5 (Squamous Non-Small Cell Lung Cancer)\n\n     Additional Inclusion Criteria For Sub-Study 2 Part A:\n* Minimum body weight ≥ 30 kg.\n* Histologically or cytologically confirmed metastatic or locally advanced\u002Frecurrent breast cancer, ovarian cancer, BTC, endometrial cancer or squamous non-small cell lung cancer.\n\nAdditional Inclusion Criteria For Sub-Study 3 Part A:\n\n* Minimum body weight ≥ 30 kg (for participants enrolled in cohorts including rilvegostomig only).\n* Histologically or cytologically confirmed metastatic or locally advanced\u002Frecurrent breast cancer, ovarian cancer, BTC, endometrial cancer or squamous non-small cell lung cancer.\n\nAdditional Inclusion Criteria For Sub-Study 4 Part A:\n\n* Minimum body weight ≥ 30 kg (for participants enrolled in cohorts including rilvegostomig only).\n* Histologically or cytologically confirmed metastatic or locally advanced\u002Frecurrent breast cancer, endometrial cancer or squamous non-small cell lung cancer.\n* Participants must have progressed following at least one but no more than 3 prior lines of treatment for metastatic or relapsed disease and have no satisfactory alternative treatment option as judged by the Investigator.\n\nKey Exclusion Criteria:\n\n* Treatment with any of the following:\n\n  1. Nitrosourea or mitomycin C within 6 weeks prior to the first dose of study treatment\n  2. Any investigational agents or study drugs from a previous clinical study within 5 half-lives or 28 days (whichever is shorter) prior to the first dose of study treatment\n  3. Any other anticancer treatment within the following time periods prior to the first dose of study intervention:\n\n     1. Cytotoxic treatment: 21 days\n     2. Non-cytotoxic drugs: 21 days or 5 half-lives (whichever is shorter)\n     3. Biological products including immuno-oncology agents: 28 days\n* Spinal cord compression or a history of leptomeningeal carcinomatosis.\n* Brain metastases unless treated, asymptomatic, stable, and not requiring continuous corticosteroids at a dose of \\> 10 mg prednisone\u002Fday or equivalent for at least 4 weeks prior to start of study.\n* Active infection including tuberculosis and HBV, HCV or HIV\n* History of (non-infectious) ILD\u002Fpneumonitis that required steroids, has current ILD\u002Fpneumonitis, or where suspected ILD\u002Fpneumonitis cannot be ruled out by imaging at screening.\n* Clinically severe pulmonary compromise resulting from intercurrent pulmonary illnesses\n* Participants with any of the following cardiac criteria:\n\n  1. History of arrhythmia which is symptomatic or requires treatment (NCI CTCAE v5.0 Grade 3); symptomatic or uncontrolled atrial fibrillation, or asymptomatic sustained ventricular tachycardia.\n  2. Uncontrolled hypertension.\n  3. Acute coronary syndrome\u002Facute myocardial infarction, unstable angina pectoris, coronary intervention procedure with percutaneous coronary intervention, or coronary artery bypass grafting within 6 months.\n  4. History of brain perfusion problems (eg, carotid stenosis) or stroke, or transient ischemic attack in the last 6 months prior to screening.\n  5. Symptomatic heart failure (NYHA class ≥ 2).\n  6. Prior or current cardiomyopathy.\n  7. Severe valvular heart disease.\n  8. Mean resting QTcF \\> 470 msec.\n  9. Risk factors for QTc prolongation or risk of arrhythmic events such as heart failure, congenital long QT syndrome, family history of long QT syndrome or unexplained sudden death under 40 years of age.\n* Patients with history of myelodysplastic syndrome (MDS)\u002Facute myeloid leukemia (AML) or with features suggestive of MDS\u002FAML (as determined by prior diagnostic investigation)\n\nAdditional Exclusion Criteria For Sub-Study 2 Part A:\n\n* Thromboembolic event within 3 months before the first dose of study intervention - No longer applicable per amendment 7\n* Experienced a toxicity that led to permanent discontinuation of prior immunotherapy.\n* Active or prior documented autoimmune or inflammatory disorders requiring chronic treatment with steroids or other immunosuppressive treatment.\n* History of organ transplant\n\nAdditional Exclusion Criteria For Sub-Study 2 Part B\n\n• Previous treatment with any therapy that contains a TOP1i (eg. irinotecan, topotecan, trastuzumab deruxtecan, etc.)\n\nAdditional Exclusion Criteria For Sub-Study 3 Part A:\n\n* Concomitant use of medications or herbal supplements known to be strong cytochrome P (CYP) 3A4 inducers\u002Finhibitors.\n* Any history of persisting (\\> 2 weeks) severe cytopenia due to any cause\n* Patients with any known predisposition to bleeding\n* Refractory nausea and vomiting, chronic gastrointestinal diseases, inability to swallow the formulated product or previous significant bowel resection that would preclude adequate absorption of saruparib.\n* Previous treatment with any therapy that contains a TOP1i (eg. irinotecan, topotecan, trastuzumab deruxtecan, etc.)\n\nAdditional Exclusion Criteria For Sub-Study 4 Part A:\n\n* Patients have received prior therapy with AZD9574 or more than 1 prior line of any other PARPi-based regimen\n* Concomitant use of medications or herbal supplements known to be strong cytochrome P (CYP) 3A4 inducers\u002Finhibitors.\n* Previous treatment with rilvegostomig for the cohort treated with rilvegostomig\n* Previous treatment with any therapy that contains a TOP1i (eg. irinotecan, topotecan, trastuzumab deruxtecan, etc.)\n* Refractory nausea and vomiting, chronic gastrointestinal diseases, inability to swallow the formulated product or previous significant bowel resection that would preclude adequate absorption of AZD9574",{"count":571,"type":23},460,[26,27],"This research study is studying a new compound, AZD8205, as a possible treatment for advanced or metastatic solid tumours alone or in combination with anti-cancer agents",[152,575,30,32,576],"Biliary Tract Carcinoma","Squamous Non-Small Cell Lung Cancer",[578],"First In Human, antibody drug conjugate, cancer, solid tumour, Phase I, Phase IIa",{"date":510,"type":51},{"date":581,"type":51},"2021-10-18",{"date":583,"type":23},"2027-09-29",{"name":57,"class":58},67,{"id":587,"slug":588,"hasResults":12,"nctId":589,"briefTitle":590,"officialTitle":591,"acronym":4,"eligibilityCriteria":592,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":593,"targetDuration":4,"studyType":24,"phases":595,"briefSummary":596,"conditions":597,"keywords":4,"overallStatus":47,"whyStopped":4,"lastUpdateSubmitDate":609,"lastUpdatePostDateStruct":610,"startDateStruct":611,"completionDateStruct":613,"leadSponsor":615,"locationsCount":413},"100534718","phase-1-a-study-of-mgc026-in-participants-with-advanced-solid-tumors-100534718","NCT06242470","A Study of MGC026 in Participants With Advanced Solid Tumors","A Phase 1\u002F1b First-in-Human, Open Label, Dose Escalation and Cohort Expansion Study of MGC026 in Participants With Advanced Solid Tumors","Inclusion Criteria:\n\n* Adults ≥ 18 years old, able to provide informed consent\n* Adequate performance and laboratory parameters\n* Availability of archival or formalin-fixed paraffin-embedded tumor tissue sample. Participants may undergo a fresh tumor biopsy to obtain a specimen for testing if an archival tumor sample is not available. Participants with no available archival tissue sample who cannot safely undergo a fresh biopsy as determined by consultation between the sponsor and investigator are eligible\n* Unresectable, locally advanced or metastatic solid tumors including: squamous cell cancer (SCC) of the head and neck, esophageal SCC, squamous and non-squamous non-small cell lung cancer, small cell lung cancer, bladder cancer, sarcoma, endometrial cancer, melanoma, castration resistant prostate cancer, breast cancer, ovarian cancer, cervical cancer, colorectal cancer gastric or gastroesophageal cancer, pancreatic carcinoma, clear cell renal cell cancer or hepatocellular cancer.\n* Measurable disease per RECIST v1.1. Participants with metastatic CRPC without measurable disease are eligible.\n* Must be willing to use highly effective methods of birth control from the time of consent through 7 months after discontinuation of MGC026.\n* Not pregnant or breastfeeding.\n\nExclusion Criteria:\n\n* Any underlying medical or psychiatric condition impairing participant's ability to receive, tolerate, or comply with the planned treatment or study procedures.\n* Another cancer that required treatment within the past 2 years, with the exception of those with low risk of cancer spreading or death such as adequately treated non melanomatous skin cancer, localized prostate cancer (Gleason Score \\\u003C 6), or carcinoma in situ.\n* Patients with history of prior central nervous system (CNS) metastasis must have been treated, be asymptomatic, and not have concurrent treatment for CNS disease, progression of CNS metastases on magnetic resonance imaging, computed tomography or positron emission tomography, or history of leptomeningeal disease or cord compression at the time of enrollment.\n* Treatment with surgery, systemic cancer therapy, immunotherapy, chimeric antigen receptor-T therapy, or anti-hormonal within protocol specified intervals.\n* Prior treatment with any B7-H3 targeted agent for cancer or any ADC with a topoisomerase payload.\n* Prior autologous or allogeneic stem cell or solid organ transplant.\n* Clinically significant cardiovascular, pulmonary, or gastrointestinal disorders.\n* Active viral, bacterial, or systemic fungal infection requiring parenteral treatment within 1 week of first study drug administration.\n* Known history of hepatitis B or C infection or known positive test for hepatitis B surface antigen or core antigen, or hepatitis C polymerase chain reaction.\n* Known positive testing for human immunodeficiency virus or history of acquired immune deficiency syndrome.\n* History of primary immunodeficiency.\n* Major trauma or major surgery within 4 weeks of first study drug administration.\n* Known hypersensitivity to recombinant proteins.",{"count":594,"type":23},250,[26],"The study is designed to understand the safety, tolerability, pharmacokinetics, immunogenicity, and preliminary antitumor activity of MGC026 in participants with relapsed or refractory, unresectable, locally advanced or metastatic solid tumors The study has a dose escalation portion and a cohort expansion portion of the study.\n\nParticipants will receive MGC026 by intravenous (IV) infusion. The dose of MGC026 will be assigned at the time of enrollment. Participants may receive up to 35 treatments if there are no severe side effects and as long as the cancer does not get worse. Participants will be monitored for side effects, and progression of cancer, have blood samples collected for routing laboratory work, and blood samples collected for research purposes.",[232,598,599,600,601,80,153,602,32,233,603,79,76,235,604,605,606,75,607,152,30,608],"Advanced Cancer","Metastatic Cancer","Squamous Cell Carcinoma of Head and Neck","Non Small Cell Lung Cancer","Sarcoma","Castration Resistant Prostatic Cancer","Gastro-esophageal Cancer","Pancreas Cancer","Clear Cell Renal Cell Carcinoma","Platinum-resistant Ovarian Cancer","Esophageal Squamous Cell Cancer (SCC)","2026-08-10",{"date":532,"type":51},{"date":612,"type":51},"2024-03-06",{"date":614,"type":23},"2028-10",{"name":616,"class":58},"MacroGenics",{"id":618,"slug":619,"hasResults":12,"nctId":620,"briefTitle":621,"officialTitle":622,"acronym":4,"eligibilityCriteria":623,"healthyVolunteers":12,"sex":110,"minAge":19,"maxAge":4,"enrollmentInfo":624,"targetDuration":4,"studyType":24,"phases":626,"briefSummary":627,"conditions":628,"keywords":4,"overallStatus":47,"whyStopped":4,"lastUpdateSubmitDate":609,"lastUpdatePostDateStruct":629,"startDateStruct":630,"completionDateStruct":632,"leadSponsor":634,"locationsCount":637},"100488506","phase-2-adjuvant-therapy-in-pole-mutated-and-p53-wildtypensmp-early-stage-endometrial-cancer-rainbo-blue--taper-100488506","NCT05640999","Adjuvant Therapy in POLE-Mutated and p53-Wildtype\u002FNSMP Early Stage Endometrial Cancer RAINBO BLUE & TAPER","A Phase II Study of Tailored Adjuvant Therapy in POLE-Mutated and p53-Wildtype\u002FNSMP Early Stage Endormetrial Cancer (RAINBO BLUE & TAPER)","Inclusion Criteria:\n\n* Patients must have had surgery consisting of hysterectomy and bilateral salpingo-oophorectomy. Lymph node dissection can be performed as per institutional standards. There must be no macroscopic residual disease after surgery.\n* Patients must have histologically confirmed Stage I to III endometrial carcinoma which can be endometrioid, serous, clear cell, un\u002Fdedifferentiated, carcinosarcoma or mixed.\n* Patients' Eastern Cooperative Group (ECOG) performance status must be 0, 1, or 2.\n* HIV-infected patients on effective anti-retroviral therapy with undetectable viral load within 6 months are eligible for this trial.\n* Patients' age must be ≥ 18 years.\n* Patient consent must be appropriately obtained in accordance with applicable local and regulatory requirements.\n* Patient is able (i.e. sufficiently fluent) and willing to complete the patient-reported outcomes (PRO) questionnaires in either English, French or a validated language\n* Patients must be accessible for treatment and follow-up. Patients enrolled on this trial must be treated and followed at the participating centre\n* Protocol treatment is to begin within 10 weeks of hysterectomy\u002Fbilateral salpingo-oophorectomy\n\nExclusion Criteria:\n\n* Prior Neoadjuvant chemotherapy for current endometrial cancer diagnosis.\n* Prior pelvic radiation.\n* Patients with a history of other malignancies, except: carcinoma in-situ without evidence of invasive disease when resected, adequately treated non-melanoma skin cancer, or other tumours curatively treated with no evidence of disease for ≥ 5 years.\n* Clinical evidence of distant metastasis as determined by pre-surgical or post-surgical imaging (CT scan of chest, abdomen and pelvis or whole-body PET-CT scan)\n* Patients with a documented positive surgical margin.\n* Patients with a documented positive peritoneal washings, if performed.",{"count":625,"type":23},393,[27],"This protocol tests de-escalated adjuvant treatment in patients with POLE-mutated or p53wt\u002FNSMP (p53 wildtype\u002Fno specific molecular profile) early-stage endometrial cancer (EC). Patients may be enrolled in one of two sub-studies\n\n* EN10.A\u002FRAINBO BLUE: POLE-mutated EC\n* EN10.B\u002FTAPER: p53 wildtype \u002F NSMP EC",[32],{"date":532,"type":51},{"date":631,"type":51},"2022-12-19",{"date":633,"type":23},"2029-06-30",{"name":635,"class":636},"Canadian Cancer Trials Group","NETWORK",118,{"id":639,"slug":640,"hasResults":12,"nctId":641,"briefTitle":642,"officialTitle":643,"acronym":644,"eligibilityCriteria":645,"healthyVolunteers":12,"sex":110,"minAge":19,"maxAge":4,"enrollmentInfo":646,"targetDuration":4,"studyType":113,"phases":4,"briefSummary":648,"conditions":649,"keywords":4,"overallStatus":47,"whyStopped":4,"lastUpdateSubmitDate":650,"lastUpdatePostDateStruct":651,"startDateStruct":652,"completionDateStruct":654,"leadSponsor":656,"locationsCount":657},"100596142","an-observational-study-of-molecular-profiling-of-advanced-and-aggressive-endometrial-cancer-and-1-st-line-treatment-approaches-in-russian-federation-100596142","NCT07041606","An Observational Study of Molecular profIling of Advanced and aggRessive ENdometrial Cancer and 1-st Line Treatment Approaches in Russian Federation","Multicenter, Observational, Prospective Study of Molecular Profiling in Advanced and Aggressive Endometrial Cancer Patients and 1-st Line Treatment Approaches in Russian Federation","IREN","Inclusion Criteria:\n\n1. Female patients aged ≥ 18 years old;\n2. Signed ICF, including consent for archival FFPE tumor tissue block testing;\n3. Newly diagnosed, histologically confirmed, advanced (III-IV stage) EC, with the date of diagnosis of histologically confirmed disease within 4 months before inclusion;\n4. Endometrioid type G3 or any non-endometrioid histological type of EC (such as serous carcinoma, clear cell carcinoma, mixed carcinoma, undifferentiated and dedifferentiated carcinoma, carcinosarcoma, others);\n5. The presence of biopsy or postoperative archival FFPE tumor sample (block);\n6. Availability of source medical documentation.\n\nExclusion Criteria:\n\n1\\. Patients participating in clinical (interventional) studies since the diagnosis of histologically confirmed, advanced EC.",{"count":647,"type":23},500,"Multicenter, observational, prospective study of molecular profiling in advanced and aggressive endometrial cancer patients and 1-st line treatment approaches in Russian Federation",[32],"2026-08-07",{"date":609,"type":51},{"date":653,"type":51},"2025-06-24",{"date":655,"type":23},"2027-06-30",{"name":57,"class":58},19,{"id":659,"slug":660,"hasResults":12,"nctId":661,"briefTitle":662,"officialTitle":663,"acronym":664,"eligibilityCriteria":665,"healthyVolunteers":12,"sex":110,"minAge":19,"maxAge":4,"enrollmentInfo":666,"targetDuration":4,"studyType":24,"phases":667,"briefSummary":668,"conditions":669,"keywords":670,"overallStatus":47,"whyStopped":4,"lastUpdateSubmitDate":650,"lastUpdatePostDateStruct":684,"startDateStruct":685,"completionDateStruct":687,"leadSponsor":689,"locationsCount":690},"100592106","phase-3-destiny-endometrial01-a-phase-iii-study-of-trastuzumab-deruxtecan-plus-rilvegostomig-or-pembrolizumab-as-first-line-treatment-of-her2-expressing-ihc-32-mismatch-repair-proficient-pmmr-endometrial-cancer-100592106","NCT06989112","DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+\u002F2+), Mismatch Repair Proficient (pMMR) Endometrial Cancer","DESTINY-Endometrial01: An Open-Label, Sponsor-Blinded, Randomized, Controlled, Multicenter, Phase III Study of Trastuzumab Deruxtecan (T-DXd) Plus Rilvegostomig or Pembrolizumab vs Chemotherapy Plus Pembrolizumab as First-Line Therapy of HER2-Expressing (IHC 3+\u002F2+), Mismatch Repair Proficient (pMMR), Primary Advanced or Recurrent Endometrial Cancer","DE-01","Key Inclusion Criteria:\n\n* ≥ 18 years of age at the time of screening. Other age restrictions may apply as per local regulations.\n* Histologically confirmed diagnosis of epithelial endometrial carcinoma. All histologies are allowed except for sarcomas (carcinosarcomas are allowed).\n* Participant must have primary advanced disease (Stage III\u002FIV) or recurrent endometrial cancer and meet at least one of the following criteria:\n\n  1. Primary Stage III (per FIGO 2023) disease with measurable disease at baseline per RECIST 1.1 based on the investigator's assessment.\n  2. Primary Stage IV (per FIGO 2023) disease regardless of presence of measurable disease at baseline.\n  3. Recurrent disease regardless of presence of measurable disease at baseline.\n* Endometrial cancer with HER2 IHC expression of 3+ or 2+ by prospective central testing.\n* Endometrial cancer that is determined pMMR by prospective central testing.\n* Provision of an adequate FFPE tumor tissue sample for central HER2, MMR, and PD-L1 IHC testing.\n* Prior therapy:\n\n  1. No prior chemotherapy for the treatment of EC, except for one prior line of adjuvant\u002F neoadjuvant chemotherapy with curative intent (chemotherapy or chemoradiation) if completed ≥ 6 months prior to signature of the main ICF. Prior trastuzumab in the adjuvant\u002Fneoadjuvant setting is allowed.\n  2. No prior exposure to antibody-drug conjugates or immune checkpoint inhibitors\n  3. Participants may have received prior radiation therapy for the treatment of endometrial cancer. Adequate treatment washout period is required\n  4. Participants may have received prior hormonal therapy for the treatment of endometrial cancer. Adequate treatment washout period is required\n* ECOG 0-1.\n* Left ventricular ejection fraction ≥ 50% within 28 days before randomization.\n* Adequate organ and bone marrow function within 14 days before randomization.\n* The participant is not considered a candidate for curative therapy in the judgment of the investigator.\n\nKey Exclusion Criteria:\n\n* Any severe or uncontrolled systemic diseases which, in the investigator's opinion, makes it undesirable for the participant to participate in the study or would jeopardize compliance with the protocol.\n* Active or ongoing serious chronic gastrointestinal conditions associated with diarrhea, primary immunodeficiency, or non-infectious skin disease requiring systemic treatment.\n* Active or prior documented autoimmune or inflammatory disorders requiring chronic systemic treatment with the use of disease-modifying agents, corticosteroids, or immunosuppressive drugs.\n* History of (non-infectious) ILD\u002Fpneumonitis that required steroids, current ILD\u002Fpneumonitis, or suspected ILD\u002Fpneumonitis that cannot be ruled out by imaging at screening.\n* Lung criteria:\n\n  1. Lung-specific intercurrent clinically significant illnesses including, but not limited to, any underlying pulmonary disorder (e.g., pulmonary emboli within 3 months of the study enrollment, severe asthma, severe chronic obstructive pulmonary disease \\[COPD\\], restrictive lung disease, etc.).\n  2. Any autoimmune, connective tissue or inflammatory disorders where there is documented, or a suspicion of pulmonary involvement at the time of screening.\n  3. Prior pneumonectomy (complete).\n* History of myocardial infarction or unstable angina within 6 months before randomization, or symptomatic congestive heart failure (NYHA Class II to IV), clinically significant arrhythmia, uncontrolled hypertension, cardiomyopathy of any etiology or history of myocarditis.\n* History of organ transplant or allogeneic stem cell transplant.\n* Spinal cord compression or clinically active central nervous system metastases. Participants with clinically inactive brain metastases may be included in the study.\n* Evidence of any of the following infections:\n\n  1. Active tuberculosis\n  2. HIV infection that is not well controlled.\n  3. Active hepatitis B or C infection.",{"count":449,"type":23},[451],"DESTINY-Endometrial01 will investigate the efficacy of first-line T-DXd + rilvegostomig (Arm A) and\u002For T-DXd+ pembrolizumab (Arm B) when compared to chemotherapy (carboplatin + paclitaxel) + pembrolizumab (Arm C), by assessment of progression free survival (PFS), as assessed by BICR, in participants with HER2-expressing (IHC 3+\u002F2+), pMMR, primary advanced (Stage III\u002FIV) or recurrent EC.",[32],[32,671,672,673,459,674,675,676,677,678,679,680,681,46,43,682,683],"Uterine Cancer","Endometrial Carcinoma","Human epidermal growth factor receptor 2 (HER2)","Trastuzumab deruxtecan","T-DXd","DS-8201a","Anti-HER2-Antibody Drug Conjugate(ADC)","DESTINY-Endometrial01","Programmed Cell Death-1 (PD1, PD-1)","Immune checkpoint inhibitor","TIGIT","Paclitaxel","Rilvegostomig",{"date":532,"type":51},{"date":686,"type":51},"2025-03-27",{"date":688,"type":23},"2031-02-19",{"name":57,"class":58},252,{"id":692,"slug":693,"hasResults":12,"nctId":694,"briefTitle":695,"officialTitle":696,"acronym":4,"eligibilityCriteria":697,"healthyVolunteers":12,"sex":18,"minAge":698,"maxAge":4,"enrollmentInfo":699,"targetDuration":4,"studyType":24,"phases":700,"briefSummary":701,"conditions":702,"keywords":720,"overallStatus":47,"whyStopped":4,"lastUpdateSubmitDate":650,"lastUpdatePostDateStruct":748,"startDateStruct":749,"completionDateStruct":751,"leadSponsor":753,"locationsCount":755},"100407463","the-evaluation-of-pc14586-in-patients-with-advanced-solid-tumors-harboring-a-tp53-y220c-mutation-pynnacle-100407463","NCT04585750","The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)","A Phase 1\u002F2 Open-label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of PC14586 in Patients With Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)","Inclusion Criteria:\n\n* At least 18 years of age or 12 to 17 years of age after Safety Review Committee approval.\n* Locally advanced or metastatic solid malignancy with a TP53 Y220C mutation\n* Eastern Cooperative Oncology Group (ECOG) status of 0 or 1\n* Previously treated with one or more lines of anticancer therapy and progressive disease\n* Adequate organ function\n* Measurable disease per RECIST v1.1 (Phase 2)\n\nAdditional Criteria for Inclusion in Phase 1b (rezatapopt) + pembrolizumab combination)\n\n* Anti-PD-1\u002FPD-L1 naive or must have progressed on treatment\n* Measurable disease\n\nExclusion Criteria:\n\n* Anti-cancer therapy within 21 days (or 5 half-lives) of receiving the study drug\n* Radiotherapy within 14 days of receiving the study drug\n* Primary CNS tumor\n* History of leptomeningeal disease or spinal cord compression\n* Brain metastases, unless neurologically stable and do not require steroids to treat associated neurological symptoms\n* Stroke or transient ischemic attack within 6 months prior to screening\n* Heart conditions such as unstable angina within 6 months prior to screening, uncontrolled hypertension, a heart attack within 6 months prior to screening, congestive heart failure, prolongation of QT interval, or other rhythm abnormalities\n* Strong CYP3A4 inducers and strong CYP2C9 inhibitors\u002Finducers within 14 days of first dose of rezatapopt\n* History of gastrointestinal (GI) disease that may interfere with absorption of study drug or patients unable to take oral medication\n* History of prior organ transplant\n* Known, active malignancy, except for treated cervical intraepithelial neoplasia, or non-melanoma skin cancer\n* Known, active uncontrolled Hepatitis B, Hepatitis C, or human immunodeficiency virus infection\n\nAdditional Criteria for Exclusion from Phase 2 (rezatapopt monotherapy)\n\n* Known KRAS mutation, defined as a single nucleotide variant (SNV) (Phase 2)\n\nAdditional Criteria for Exclusion from Phase 1b (rezatapopt) + pembrolizumab combination)\n\n* Received prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent or with an agent directed to another stimulatory or co-inhibitory T-cell receptor and discontinued from that treatment due to a Grade 3 or higher immune-related AE (irAE)\n* Received a live or live-attenuated vaccine within 30 days prior to the first dose of study intervention\n* Diagnosis of immunodeficiency or receiving chronic systemic steroid therapy within 7 days prior to the first dose of study drug\n* Hypersensitivity (≥ Grade 3) to pembrolizumab and\u002For any of its excipients\n* Active autoimmune disease that has required systemic treatment in past 2 years\n* History of radiation pneumonitis\n* History of (non-infectious) or active pneumonitis \u002F interstitial lung disease that required steroids\n* Active infection requiring systemic therapy\n* Known history of HIV infection\n* Has previously received rezatapopt","12 Years",{"count":346,"type":23},[26,27],"The Phase 2 monotherapy portion of this study is currently enrolling and will evaluate the efficacy and safety of PC14586 (INN rezatapopt) in participants with locally advanced or metastatic solid tumors harboring a TP53 Y220C mutation. The Phase 1 portion of the study will assess the safety, tolerability and preliminary efficacy of multiple dose levels of rezatapopt as monotherapy and in Phase 1b in combination with pembrolizumab.",[232,703,599,704,154,30,32,155,76,152,705,706,234,707,708,709,710,87,711,712,713,81,92,714,210,715,716,717,718,719],"Advanced Malignant Neoplasm","Metastatic Solid Tumor","Other Cancer","Locally Advanced","Gall Bladder Cancer","Small Cell Lung Cancer","Small Cell Lung Cancer ( SCLC )","Small Cell Lung Carcinoma","NSCLC (Non-small Cell Lung Cancer)","SCLC","Non-Small Cell Lung Carcinoma","HER2+ Breast Cancer","ER\u002FPR Positive Breast Cancer","HER2- Breast Cancer","HER2-positive Breast Cancer","HER2-negative Breast Cancer","ER\u002FPR(+), Her2(-) Breast Cancer",[721,722,723,403,724,725,726,727,728,729,730,731,732,733,734,735,736,737,738,739,740,741,742,743,744,745,746,747],"PC14586","p53","Y220C","Phase 1\u002F2","PMV","PMV Pharma","p53 mutation","TP53","TP53 mutation","p53 mutant","p53 reactivator","pembrolizumab","Keytruda","combination","PD-1","PD-L1","anti-PD-1","Merck","MSD","IgG4","mAb","Phase 1b","NGS","Next Generation Sequencing","precision","Phase 2","Rezatapopt",{"date":609,"type":51},{"date":750,"type":51},"2020-10-29",{"date":752,"type":23},"2027-12-31",{"name":754,"class":58},"PMV Pharmaceuticals, Inc",77,{"id":757,"slug":758,"hasResults":12,"nctId":759,"briefTitle":760,"officialTitle":761,"acronym":4,"eligibilityCriteria":762,"healthyVolunteers":12,"sex":110,"minAge":19,"maxAge":763,"enrollmentInfo":764,"targetDuration":4,"studyType":24,"phases":766,"briefSummary":767,"conditions":768,"keywords":771,"overallStatus":47,"whyStopped":4,"lastUpdateSubmitDate":774,"lastUpdatePostDateStruct":775,"startDateStruct":776,"completionDateStruct":778,"leadSponsor":780,"locationsCount":171},"100558341","pd-1-inhibitor-combined-with-progesterone-treatment-in-fst-for-patients-with-mmrd-endometrial-cancer-100558341","NCT06549855","PD-1 Inhibitor Combined With Progesterone Treatment in FST for Patients With MMRd Endometrial Cancer","PD-1 Inhibitor Combined With Progesterone Treatment in Fertility Sparing Therapy for Mismatch Repair-deficient Endometrial Cancer","Inclusion Criteria:\n\n* Be between the ages of 18-45 years old;\n* Stage IA (FIGO 2009) ;\n* Confirmed diagnosis of endometrial adenocarcinoma G1-G2 based upon D\\&C or hysteroscopy;\n* Molecular classification of MMRd, determined by immunohistochemical (IHC) for MMR proteins and by the second generation sequencing (NGS) or microsatellite polymerase chain reaction (PCR);\n* With a strong desire for fertility preservation;\n* Sign the informed consent.\n\nExclusion Criteria:\n\n* Stage IB(FIGO 2009) and above；\n* Tumour differentiation of G3 or non-endometrioid adenocarcinoma；\n* Complicated with any other malignancy；\n* Contraindicated to conservative treatment or the use of pharmaceuticals.\n* Contraindications to pregnancy, or judged by the researcher to be unfit for pregnancy or delivery.","45 Years",{"count":765,"type":23},10,[149],"The objective of this study was to investigate the feasibility of a PD-1 inhibitor in combination with progesterone as a means of preserving fertility in patients with early-stage mismatch repair-deficient (MMRd) endometrial cancer who wish to preserve fertility.",[32,769,770],"Endometrioid Carcinoma","Mismatch Repair Deficiency",[772,769,773],"Fertility preservation","PD-1 inhibitor","2026-08-06",{"date":609,"type":51},{"date":777,"type":51},"2024-09-02",{"date":779,"type":23},"2029-10",{"name":781,"class":170},"Peking University People's Hospital"]